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ABSTRACT 
 
 
Bioprosthetic heart valves (BHVs) fail within 12-15 years of implantation due to 
limited durability.  This limits their application to elderly population.  Younger patients 
with contraindications for long-term anticoagulant therapy necessary for mechanical 
heart valves may also receive BHVs. Investigation into improving valve durability can 
lead to longer implant life, increased quality of life for patients receiving BHVs, and a 
broadened patient demographic. 
Current BHVs are chemically treated with glutaraldehyde (GLUT) to stabilize 
collagen via chemical crosslinking and to reduce tissue antigenicity.  GLUT fails to 
adequately stabilize elastin and glycosaminoglycans (GAGs), essential extracellular 
matrix components for valve function and durability.  Degradation of elastin also 
increases elastin-oriented calcification.  Previous use of neomycin and carbodiimide 
crosslinking has improved GAG stability. Similarly, use of pentagalloyl glucose (PGG), a 
plant polyphenol, has previously improved elastin stability in aortic wall and abdominal 
aortic aneurysm.  We have focused on long term GAG stability using neomycin and 
carbodiimide crosslinking to replace GLUT, and the use of neomycin and PGG along 
with GLUT to stabilize elastin. 
The first study shows improved long term GAG stability when tissue treated with 
neomycin and carbodiimide crosslinking is stored for ten months or implanted 
subdermally in rats for up to 15 weeks.  The second study evaluated stabilization of all 
extracellular matrix components against enzymatic degradation in an in vivo model, 
mechanical properties, and calcification potential and extracellular matrix stability in a rat 
 iii 
subdermal model.  This study demonstrated a marked increase in extracellular matrix 
stability when compared to GLUT control.  Further, the changes we saw to mechanical 
properties can be attributed to specific crosslinking modalities.  Neomycin, PGG and 
GLUT crosslinked tissue also demonstrated increased calcification potential in a rat 
subdermal model when compared to GLUT controls. 
In these studies we present two viable heart valve fixation techniques.  One 
replaces GLUT with carbodiimide based chemistry, to stabilize GAGs and remove 
negative effects caused by GLUT.  The other adds neomycin and PGG to GLUT to 
stabilize elastin and GAGs in bioprosthetic heart valve leaflets.  By stabilizing these 
components, in vivo tissue and valve mechanics may improve, accompanied by an 
increase in valve durability.  
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1 
CHAPTER ONE 
 
LITERATURE REVIEW 
 
1.1 Anatomy of the Heart 
The cardiovascular system can be divided into two parts: the heart and the 
vasculature.  The human heart is a four chambered biomechanical pump which provides 
continuous blood flow to the rest of the body [1].  The vasculature is a highly complex 
branched network of blood vessels which delivers blood and nutrients to all regions of the 
body.  During each cycle the heart experiences high pressures, which impose stress on the 
walls and valves.  Through an average lifespan of 70 years, the heart beats approximately 
2.6 billion times [2].  This incredible number of iterations makes the heart the most 
heavily used and fatigued muscle in the body. 
Comprised of four chambers and four valves, the heart is a complex organ.  Blood 
flows through a complex route, empties into the heart via the atria, and exits through the 
ventricles.  Deoxygenated blood enters the heart from the body via the vena cava and 
empties into the right atrium.  A pressure gradient then drives flow through the tricuspid 
valve into the right ventricle [1,3,4]. The heart contracts to push blood through the 
pulmonary valve and into the pulmonary artery.  This is the only artery with oxygen 
deficient blood, used to carry blood to the lungs for oxygenation.  Blood returns to the 
heart via the pulmonary vein, empties into the left atrium, and a pressure gradient drives 
flow through the mitral valve into the left ventricle.  Ventricular contractions force blood 
through the aortic valve and into the aorta, which delivers blood to secondary arteries.  
[1,3,4] 
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Figure 1.1.  Functional diagram of blood flow through the heart [5]. 
 
It is important to note how each valve controls the flow of blood through the heart 
(Figure 1.1).  The four valves can be divided into two categories: the atrioventricular 
valves and the semilunar valves.  The mitral and tricuspid valves are called the 
atrioventricular valves because they lie between the atrium and ventricle. The aortic and 
pulmonary valves are called the semilunar valves and lie in the arteries leaving the heart.  
Two primary heart actions drive flow: diastole and systole.  During diastole the 
atrioventricular valves remain closed as the blood flows into the atria.  Consequently, this 
causes the atrial pressure to increase.  The atrioventricular valves open when atrial 
pressure exceeds intraventricular pressure; this pressure gradient drives blood flow into 
the ventricles.  However, the pressure gradient alone only ejects 80% of the blood.  Atrial 
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contraction provides the force to expel the remaining 20% of blood volume into the 
ventricles. Atrioventricular valves then close to prevent backflow into the atria, during 
systole [1,3,4]. 
A similar pressure based mechanism controls the opening and closing of the 
semilunar valves.  After the blood flows into the ventricles and the atrioventricular valves 
close, insufficient pressure exists to open the semilunar valves.  Therefore, ventricular 
contraction exerts the force and pressure necessary to eject the blood into the pulmonary 
artery and aorta.  The semilunar valves open when the ventricular pressure exceeds 
pressure in the pulmonary artery or aorta.  This causes the pressure in the ventricles to 
drop rapidly, and create negative pressure between the ventricle and either pulmonary 
artery or aorta, which closes the valve [1,3,4].] 
 
1.1.1 Heart Valves 
Leaflets attached to cardiac wall and fibrous skeleton comprise the heart valves 
(Figure 1.2).  Leaflets are also called cusps, and open or close to prevent blood flow.  The 
aortic, pulmonary, and tricuspid valves each have three leaflets, while the mitral, also 
known as bicuspid, valve has two leaflets.  Coaptation occurs when each valve closes and 
the leaflet edges come together to seal the valve shut.  Leaflet flexibility allows the seal 
to form and allows the leaflets to lie against the wall of the chamber or artery during 
blood flow.  The wide range of stresses the valves experience, combined with their 
durability, makes them quite remarkable.  They maintain function well despite constant 
blood flow, high pressure gradients, blood interactions at the valve surface, and other 
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various environmental changes.  This high level of stress, seen constantly through several 
billion cycles over an average of seventy years, necessitates a highly durable and 
specialized structure.  
 
Figure 1.2. Cross section of fibrous skeleton and heart valves [3]. 
 
The focus of this review will mainly be on the aortic valve, but it is also important 
to understand the specialized structures in the other valves.  The atrioventricular valves 
are larger and more flexible than the semilunar valves, and they require a specialized 
structure called the subvalvular apparatus to prevent prolapse.  Atrioventricular valve 
prolapse is an event where the leaflets invert and extend back into the atria.  The 
subvalvular apparatus contains chordae tendineae, or tendon-like structures, and the 
papillary muscles.  The leaflets in these valves are connected to papillary muscles via the 
chordae tendineae.  The papillary muscles are located in the ventricles, and contract to 
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prevent prolapse.  During systole the chordae tendinae are relaxed.  However, during 
diastole, the low pressure in the atria causes the flaps to attempt to invert; the chordae 
tendineae tighten to prevent this event. 
       
Figure 1.3. Aortic valve leaflet.  (A) Cross section of the leaflet showing the organization 
of the three layers. (B) Photograph of a leaflet showing the radial and circumferential 
directions [6]. 
 
The aortic valve controls flow between the left ventricle and the aorta, dividing 
flow from the heart into the vasculature.  The leaflets are actually an extension of the 
fibrous skeleton, and are attached via a fibrous ring called the aortic annulus [3,7,8].  This 
load bearing structure helps transfer stresses from the valve to the aortic wall.  Aortic 
sinuses are dilations of the ascending aorta, located adjacent to the cusps [2,9]. They help 
prevent the leaflets from sticking to the aortic wall when the valve is open, and also 
promote valve closure.  The left anterior and right anterior aortic sinuses give rise to the 
coronary arteries, and lie just above the left and right cusps, respectively.  A residual 
structure exists above the nonpulmonary cusp.  This posterior aortic sinus, or non-
 
Circumferential 
Radial 
B 
A B 
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coronary sinus, does not contain an artery, and creates different flow patterns than the 
other cusps. 
Connective tissue composes the aortic valve cusps, which are thin, nearly semi-
circular in shape.  Cusps are primarily avascular, and so collect nutrients via diffusion 
from the bloodstream.  The leaflets are complex microstructurally, but rather simple 
macrostructurally.  They are attached at the base to the aortic ring, and have a free edge 
which provides closure during coaptation.  The basal attachment region runs continuously 
along the aortic ring until it reaches the free edge.  This meeting point is called the 
commissure.  Higher complexity exists in the microstructure, containing a mixture of 
valvular interstitial cells (VICs), valvular endothelial cells (VECs) and extracellular 
matrix components (ECM) [7,8]. 
 
1.1.1.1 Extracellular Matrix Components 
The complexity of the valve leaflets becomes apparent when examining the 
extracellular matrix.  The leaflets are composed of connective tissue, and formed of a 
complex mixture of elastin, collagen, and glycosaminoglycans (GAGs) (Figure 1.4) [1,7-
9]. The durability of the valves is highly contingent upon the condition of the 
extracellular matrix, and the continual remodeling which occurs in vivo [10].  Similar to 
other connective tissue in the body, the cells present in the leaflets are responsible for 
remodeling the extracellular matrix. Each molecule provides an essential role in the 
structure, function, flexibility, and durability of the valve. 
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Figure 1.4. Extracellular matrix components. (A) Elastin diagram, showing [A] α-helix, 
[B] β-structure, and [C] desmosine bond [11]. (B) Collagen diagram demonstrating triple 
helix organization [12].  Major GAG subunits (C) chondroitin sulfate and (D) hyaluronon 
[13].  
 
1.1.1.1.1 Elastin 
Elastin is a fibrillar, lysine-, proline-, and glycine-rich protein found in many 
organs, including the circulatory system (Figure 1.4).  Elastin comprises approximately 
13% of the dry weight in adult aortic valve cusps [14].  Elastin contains protein subunits 
called tropoelastin, which polymerize to former elastin fibers.  Because of the non-polar 
A 
B 
C D 
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amino acid structure, elastin is a hydrophobic protein, and forms branches and coils at 
the secondary and tertiary level [6,15].  The coiled structure allows elastin to absorb 
high loads, maintain high strain (up to 150%), and achieves a low degree of hysteresis 
[3,9,10,14].  Therefore elastin contributes the flexibility and mechanical properties 
required for the function and cyclic behavior of heart valve leaflets. 
 
1.1.1.1.2 Collagen 
Collagen is a glycine-, proline-, and hydroxyproline-rich protein, and forms long 
chain subunits which aggregate into a triple helix (Figure 1.4).  Glycine is the smallest 
amino acid, found approximately every third residue, and plays an important role in the 
collagen’s organization into a triple-helix structure.  The small size of glycine allows it to 
fit well at the interior of each helical fiber and provides space for larger amino acid 
residues to fit in the helical structure [16,17].  High proline and hydroxyproline levels 
contribute hydrogen bonding essential to formation of the helical structure.  Wide 
variation in collagen structure has led to classification of over twenty different protein 
variants, but primarily only type I and III collagen are found in heart valve leaflets [16].  
Collagen comprises roughly 55% of adult aortic valve cusp dry weight, and exhibits a 
high tensile strength [14].  Because of the long fibril formation, collagen can only handle 
low torsional or flexural stresses, yet provides much of the durability and strength in the 
extracellular matrix [18].  Interactions between collagen and elastin are thought to 
contribute to stress resistance in the extracellular matrix. 
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1.1.1.1.3 Glycosaminoglycans 
Glycosaminoglycans (GAGs) are linear polysaccharides, composed of an amino 
sugar and uronic acid group (Figure 1.4) [19].  They can be sulfated or unsulfated, and 
form a brush-like structure around a core protein, characteristic of a class of molecules 
called proteoglycans [20,21].  GAGs are found in connective tissue throughout the body.  
GAGs are highly hydrophilic molecules which trap water to provide a hydrated 
environment and further provide high viscosity and compressibility.  They are thought to 
play a key role in shock dissipation during leaflet flexure [22,23]. 
 
1.1.1.2 Valve Cell Types 
Two cell types populate native heart valve leaflets: valvular endothelial cells, and 
valvular interstitial cells.  Valvular endothelial cells (VECs) form a single blood 
contacting layer and line the endothelium, the blood contacting surface of the aortic wall.  
They form a single blood contacting layer.  VECs present a smooth, non-thrombogenic 
surface, which allows smooth and uniform surface blood flow.  VECs also produce and 
secrete inflammatory and immune regulating proteins.  The cell layer also acts as a blood 
barrier to the non-vascularized tissue, allowing the passage of nutrients, waste, and cells 
via diffusion [1,3,9,24]. 
Vascular interstitial cells (VICs), also known as myofibroblasts, lie in the internal 
portion of the heart valve cusp.  They exhibit both smooth muscle cell and fibroblastic 
characteristics, and are responsible for maintaining the extracellular matrix in native 
valves [8,25,26].  Fibroblast-like remodeling properties drive degradation and synthesis 
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of ECM, while the contractile smooth muscle cell like properties aid in maintenance of 
internal stress [7,8].  The combination of these properties makes VICs a vital part of the 
native heart valves for maintaining proper structural composition of valve leaflets [8]. 
 
1.1.1.3 Aortic Valve Layers 
The internal framework of the aortic valve is organized into three tissue layers 
each contributes a specific and essential component of the valve’s function.  The fibrosa 
consists primarily of collagen and lies on the aortic side of the valve.  The ventricularis 
contains the highest levels of elastin of any layer, and lies on the ventricle side of the 
valve.  Between the fibrosa and the ventricularis, the spongiosa is a gel-like layer where 
glycosaminoglycans aggregate (Figure 1.3, 1.5) [2,6,7,25]. 
 
 
Figure 1.5. Aortic valve leaflet structure. (A) Histologic cross section of porcine aortic 
valve leaflet showing the three major layers.  Approximately top third is fibrosa, middle 
third is spongiosa, and bottom third is ventricularis.  (B) Diagram of collagen crimping, 
corrugations, and elastin orientation during systole and diastole [7]. 
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1.1.1.3.1 Fibrosa 
The location of the fibrosa and the forces exerted on this layer require high load 
bearing potential.  The fibrosa connects directly to the fibrous ring, acting as a load 
bearing anchor point to the aortic wall [8].  A large percentage of collagen in this layer 
provides the load bearing capacity.  Collagen bundles align circumferentially in this 
layer.  Collagen microstructure contains crimps, allowing it to expand when exposed to 
higher stresses [7].  Natural corrugations also exist, which are visible during systole, but 
disappear as collagen is stretched due to tension during diastole [7].   
 
1.1.1.3.2 Spongiosa 
The spongiosa layer lies between the ventricularis and fibrosa.  It is a gel like 
layer rich in GAGs and reputed to act as a shock absorber during leaflet flexure   
Opinions in the literature differ on whether the spongiosa is a completely separate layer 
or rather an extension of the fibrosa and ventricularis [7,20,27]..  Histological 
examination shows the spongiosa to be a separate layer, and the differences in 
composition support this view.  However, mechanical testing of valve leaflets has been 
performed where the layers have been separated, intended to elucidate the mechanical 
properties conferred by each valve layer.  In this testing, the fibrosa and ventricularis 
were separated, with remnants of the spongiosa attached to each layer [6].  This testing 
demonstrated that a high degree of interactions exists between the spongiosa and the 
other two layers, and a low fatigue life results when its components are removed.  
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Regardless of whether the spongiosa constitutes its own layer or not, it remains a vital 
component of the valve structure [7,20,28]. 
 
1.1.1.3.3 Ventricularis 
While the fibrosa bears the load, and the spongiosa helps absorb and dissipate the 
load, the ventricularis layer provides extensibility to the leaflets.  A higher degree of 
radially aligned elastin, combined with intricate collagen interactions, allows the cusp to 
expand during diastole and recoil during systole [7,10,14].  These properties are key in 
the flow mechanics of the valve, since the ventricularis stretches to increase the 
coaptation area during diastole [7,10].  The elastin in this layer also recoils during 
systole, helping minimize the size of the cusp, which maximize the cross-sectional flow 
area.   
Elastin orientation in the ventricularis maintains a natural preload in tension [29].  
The theory is that elastin tubules are likely the component preloaded, and that they 
contribute to the cups returning to the native configuration [29].  The interactions of 
elastin tubules with collagen fibers act to maintain fiber geometry between successive 
loading cycles.  Sheet elastin also exists in the ventricularis and contributes some degree 
of isotropy.  However, the interactions between the elastin tubules and collagen fibers 
dominate; therefore the mechanical properties are not uniform between radial and 
circumferential directions.  Consequently, the ventricularis is a highly anisotropic, elastic 
tissue layer, which lends extensibility and recoil to the aortic valve leaflet [6]. 
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1.1.2 Glycosaminoglycans 
Glycosaminoglycans (GAGs) are long polysaccharides which contain repeating 
disaccharide units.  The disaccharide essentially forms an alternating copolymer of 
hexosamine and a sugar (hexuronic acid or hexose) [19,30].  These molecules can be 
found distributed throughout the body, more specifically in connective tissue including 
cartilage, tendons, synovial fluid, and heart valve cusps.  GAGs can be separated into two 
classes: sulfated and nonsulfated.  The majority of GAGs are sulfated, with the major 
exception of hyaluronan.  Sulfated GAGs can be attached to central proteins to form 
proteoglycans [30].  Since hyaluronan lacks sulfate groups, it does not link to a core, but 
rather can act as the core protein [20-22]. 
 
Figure 1.6.  Bottle brush like structure of proteoglycan aggregate (A) electron 
microscopy photomicrograph [31], (B) diagram of proteoglycan aggregate structure and 
key elements [32]. 
B 
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Physiological significant GAG molecules can be classified in five different types: 
hyaluronic acid, chondroitin sulfate, dermatin sulfate, keratin sulfate, and heparin sulfate 
[21,33].  As mentioned before, heart valve based GAG molecules are primarily 
aggregated in the spongiosa layer and they can be bound to a central protein core to form 
proteoglycans.  As evidenced by electron microscopy, they form a brush-like structure 
around the core via glycosidic bonds [19].  In heart valves, hyaluronan typically forms 
the protein core while chondroitin sulfate forms the side chain brush structures [23]. 
 GAGs have an innate hydrophilicity, arising from their anionic character [22,32].  
Since GAGs typically contain both hexosamine and uronic acid, the combination of the 
amine and carboxyl groups with the sulfate groups (in sulfated GAGs) greatly contributes 
to the hydrophilicity.  This is important, because GAGs absorb water, forming a gel in the 
spongiosa layer, which is thought to contribute to shear stress and compressive force 
dissipation in native heart valve function [19,21,33-35].  It is also thought to essentially 
act as an extension of both the ventricularis and fibrosa.  The importance of GAGs in 
heart valves can also be seen when examining their role in clinical failure. 
 Characteristic features of GAGs are also important in other functions.  The 
carboxyl and sulfate groups allow GAGs to bind to proteins via amino acid residues [19].  
They have other functions in vivo, including: anticoagulant in the vasculature (heparin), 
compose and hydrate cartilage (chondroitin/keratin sulfate), synovial fluid (hyaluronan), 
and various cell surface or extracellular matrix components. 
 In the native heart valve, GAGs exhibit a high turnover rate; digestion of old 
GAGs occurs every 2-14 days [36].  New GAGs are produced by living cells within the 
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heart valve tissue.  This continuous remodeling of the GAG network remains an 
important factor in maintaining proper valve health and function. 
 
1.1.3 Elastin 
Elastin is a fibrillar protein found in connective tissue.  It is composed of 
tropoelastin subunits, and forms microfibers, which in turn form elastic fibers.  These 
fibers are protected from degradation by a glycoprotein sheath.  Elastin provides much of 
the elasticity in connective tissue as well as heart valves [8]. 
 
1.1.3.1 Structure 
The 70 kDa tropoelastin monomer contains high amounts of hydrophobic amino 
acids such as glycine, valine, alanine, lysine, and proline [37,38].  Alanine and lysine rich 
sections form α-helices, while glycine, valine, and proline rich sections form β-sheets 
[39].  The hydrophobic β-sheets are susceptible to elastases while the α-helix crosslinks 
provide native resistance to proteases.  Lysine residues arrange such that they can form 
crosslinks.  Lysyl oxidase catalyzes the oxidative deamination reaction which forms these 
crosslinks.  When adjacent to lysine, tyrosine or phenylalanine will inhibit oxidative 
deamination due to steric hindrance.  Crosslinking reactions form new amino acids: 
desmosine, isodesmosine, and lysinonorleucine.  Desmosine and isodesmosine bonds 
utilize four amino acid residues, while lysinonorleucine bonds link two residues.  Side-to-
side crosslinks form in the middle of monomers to thicken the fibers, and terminal bonds 
lengthen the elastin fibers. 
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Elastin comprises approximately 13 percent of the dry weight in healthy adult 
aortic cusps [14].  Rich in non-polar amino acids, mature elastin is hydrophobic, and 
experiences a low metabolic turnover rate with a biological half-life of nearly 70 years 
[15].  Elastin is only produced during developmental periods. After adolescence, new 
elastin synthesis rarely occurs.  Any subsequent degradation lacks sufficient remodeling 
capability, resulting in deterioration of the extracellular matrix and the progression of 
valvular disease. 
 
1.1.3.2 Function 
As its name implies, elastin fibers are responsible for the elasticity present in most 
tissues.  This property arises from alternating β-sheets and α-helices in its secondary 
structure, as well as crosslinks between its fibers (Figure 1.7) [37,38].  Elastin bears 
mechanical load at low strain [14].  It also allows recoil due to high elasticity, which is 
able to maintain up to 150% strain without failure.  Intrafibrillar connections link elastin 
and collagen to guide collagen to its natural orientation when the valve relaxes [6,14].  
Elastin fibers also help to dampen loading and unloading cycles in the tissue. 
Testing to establish elastin’s role in heart valves elucidated that elastin bears 
tension at low strains, allowing collagen fibers to uncrimp, after which collagen bears the 
load.  This is due to the lower extensibility of collagen fibers.  During the unloading 
cycle, elastin aids in returning collagen bundles to an undeformed state.  The mechanistic 
importance of elastin suggests that damage to elastin within heart valve tissue would be 
detrimental to their function and stability [40]. 
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Figure 1.7.  Diagram demonstrating elastin crosslinks in (A) relaxed and (B) stretched 
states.  In stretched state, coiled chains are brought into alignment, and chains recoil 
when relaxed [11]. 
 
1.1.3.3 Role in Calcification 
Elastin degradation diseases such as atherosclerosis, restenosis, abdominal aortic 
aneurysm and structural dysfunction in heart valves, and also plays a role in vascular 
calcification.  Elastin has a high binding affinity for calcium, which contributes to its role 
in mineralization [41,42].  The role of elastin in aortic calcification was confirmed by 
selectively removing cells or collagen from aortic wall and testing in a rat subdermal 
model.  Calcification still developed in each case, demonstrating that a mechanism other 
than cell- or collagen-oriented calcification is responsible [43].   
Elastin degradation also plays a role in calcification, possibly revealing additional 
nucleation sites.  In fact, expression of matrix metalloproteinase (MMP) 2 and 9, 
responsible for extracellular matrix remodeling, are positively correlated with elastin 
calcification [44-46].  Tenascin-C, a protein expressed in developing bone, is also active 
in calcific aortic stenosis.  This protein is active in physiological mineralization 
A B 
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formation, and its expression increases during late calcification progression [44,47].  
Degradation of elastin fibers is found in multiple vascular diseases related to 
calcification, which furthers the idea that elastin damage has a direct correlation with 
elastin calcification. 
 
Figure 1.8.  Possible mechanisms for elastin-oriented aortic valve calcification [48]. 
 
1.2 Valvular Disease Pathology and Treatment 
1.2.1 Valvular Disease 
 In 2009, over 90,000 valve replacement surgeries were performed in the United 
States alone.  This number pales in comparison to the 15 million people suffering from 
aortic or mitral valve disease.  Over 20,000 cases of valve disease result in death annually 
in the United States, and contribute to an additional 42,000 deaths [49].  Valve disease 
can be broken into two categories: valvular stenosis and valvular insufficiency.  Stenotic 
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valves are characterized by narrowing of the valve opening, typically caused by stiffening 
of the leaflets.  Valvular insufficiency, or regurgitation, is characterized by incomplete 
coaptation of the leaflets which can also be caused by stiffening, or structural degradation 
of the leaflet tissue [24]. 
 One of the most common causes of stenotic valves is calcific degeneration of the 
leaflets [50-54].  Calcific nodules form within the leaflet, creating a thick fibrotic, stiffer 
tissue (Figure 1.9).  Calcific degeneration progresses similarly to atheroma in the 
vasculature, and typically occurs in adults over 65 years of age.  Because of the stiff 
leaflets and smaller opening, the heart must pump harder to move the same amount of 
blood.  This puts increased strain on the heart, and reduces the flow of blood to the body.  
An increased pressure gradient across the valve can put greater stress on the stiffened 
leaflets and this can cause calcified fragments to break off and embolize. 
  
Figure 1.9. (A) Healthy human aortic valve [55] and (B) explanted calcified human 
aortic valve with arrow pointing to calcific nodule [56]. 
A B 
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 Stenosis and regurgitation are two ways to characterize valve disease and failure, 
but there are further contributing causes and disorders to valve disease.  These include 
rheumatic fever, infective endocarditis, myxomatous degeneration, calcific degeneration, 
and congenital anomalies.  Each of these disorders contributes to valve disease, 
predominantly affecting the highly stressed mitral and aortic valves.  Incidence of 
problems with these valves arises from the higher pressures and stress placed on the right 
side of the heart. 
Valvular diseases can be alternatively classified as congenital (preexisting at 
birth) heart defects, or acquired diseases [10,24,57].  Congenital defects are associated 
with inherited disorders and they affect approximately 3% of the population.  However, 
they are usually asymptomatic until discovered in routine examination.  The two common 
congenital defects are myxomatous mitral valves and bicuspid aortic valves [10,57].  
Further disorders affecting the valves are autoimmune and connective tissue disorders. 
Myxomatous mitral valves, commonly called floppy valves, present as prolapsed 
valves, extending back into the left atrium during contraction.  The leaflets contain 
thickened spongiosa caused by an accumulation of dermatin sulfate [10,24].  In fact, the 
term myxoma is derived from the Greek word for mucus, which contains a mixture of 
proteoglycans.  The increase of the spongiosa causes a thicker, more rubbery tissue, and 
weakens the fibrosa as collagen bundles are pushed farther apart [24].  Mitral valve 
prolapse can result in valve insufficiency, but can also be asymptomatic and cause heart 
failure [10,24]. 
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Bicuspid aortic valves appear to have only two leaflets.  This can appear as one 
normal leaflet and two leaflets fused together, or two symmetric leaflets.  Similar to 
myxomatous degeneration, bicuspid aortic valves are asymptomatic in early life unless 
observed under examination.  The presence of a bicuspid aortic valve can lead to aortic 
root dilation or cusp prolapse later in life [24,57]. 
Aside from congenital disorders, several acquired diseases affect the heart valves. 
Incidence is affected by environmental factors such as lifestyle choices and infection.  
The most common acquired diseases affecting heart valves are infective endocarditis, 
rheumatic heart disease, and degenerative diseases such as calcification and aortic root 
dilation. 
Infective endocarditis is defined as the infection and vegetation of the 
endocardium or heart valves [58-61].  The majority of infections are caused by gram-
positive cocci such as coagulase-positive Staphylococcus aureus or coagulase-negative 
Staphylococcus epidermis.  Valve leaflets have no vascular supply; consequently, 
infection must come from the blood itself.  Valve damage is a predisposing factor for 
infective endocarditis due to compromised native barriers to infection [58].  Bacteria or 
fungi can become trapped during the repair process within a network of immune cells, 
platelets, and fibrin.  These organisms cause rapid tissue destruction, leading to large 
vegetations or growths, which cause incomplete coaptation or stenosis of the valve [62].  
Larger vegetations can embolize into the bloodstream leading to side effects and further 
infection progression downstream.  Since valve damage promotes bacterial attachment, 
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conditions such as congenital heart defects, degenerative disease, rheumatic disease, and 
mechanical wear can be predisposing factors for endocarditis [24,58,62]. 
Rheumatic fever can develop in children following contraction of strep throat, 
caused by Streptococci bacteria, and it is believed to be caused by antibody cross-
reactivity [63-65].  In rare occurrences, antibodies are released which can react with 
proteins in the tissue.  Rheumatic fever can lead to rheumatic heart disease, collectively 
causing damage to all parts of the heart and valvular defects [24].  However, incidences 
affecting the joints are more common [66].  Rheumatic fever has largely been eliminated 
in first and second world countries, mainly remaining a problem in developing countries 
[67]. 
Degenerative diseases are passive disorders which cause wear, tear, and 
calcification of the valve [68].  They are more common in older patients due to tissue 
fatigue, and present as floppy valves, aortic dilation, or valve calcification.  Preexisting 
conditions such as congenital defects or other diseases increase the propensity of the 
valve to wear, experiencing quicker degeneration of the tissue [10,24,53,54,68].  Over 
25% of patients over 65 suffer from aortic calcific sclerosis [69], and roughly 43% of all 
heart valve diseases present as aortic sclerosis, or thickening of the valve [49].  Aortic 
stenosis causes include calcification and thickening of the aortic valve, and progresses 
similarly to atherosclerosis [10,53,54].  Lifestyle choices remain a significant 
contribution to the development of this disorder.  Though mostly a degenerative disease, 
calcification is also an active process influenced by phenotypic shifts of cells 
[10,53,54,70,71].  Increased macrophage activity occurs, and VICs shift to osteoblast-like 
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properties, which produce bone mineralization.  Degenerative diseases greatly interest the 
cardiac community, since they are both prevalent in native heart valve disease, and 
remain the number one mode of failure in bioprosthetic valves. 
  
1.2.2 Treatment of Valvular Disease 
Early intervention can help reduce the severity of valvular disease before it 
necessitates surgery or replacement.  Noninvasive visualization techniques such as 
echocardiography or coronary angiography can correctly identify valve disease (Figure 
1.10).  Echocardiography can show the size of the valve openings.  Doppler mode uses 
ultrasound to determine regurgitation or stenosis severity.  Coronary angiography utilizes 
an injectable contrast agent to visualize blood flow and identify a narrowed valve or 
backflow of blood.  Blood cultures and echocardiography are used to identify infective 
endocarditis. 
 
Figure 1.10. Images from non-invasive techniques for determining valvular disease. (A) 
Chest X-ray showing calcified left atrial wall, (B) transesophogeal echocardiogram 
shows echo contrast in left atrium, (C) computed Tomogram shows calcification in left 
atrium [52]. 
A B C 
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Upon identification of valvular disease, corrective actions for treatment can be 
taken.  Lifestyle changes or drug therapy affects progression of acquired diseases through 
mediating and reducing the severity of symptoms.  A variety of percutaneous 
interventional methods exist.  One such example is balloon valvuloplasty, which works 
similarly to angioplasty to help reopen stenotic valves.  This treatment is most commonly 
used in the tricuspid, pulmonary, and mitral valves.  Risk for embolism exists in valves 
with vegetations or calcific deposits.  Surgical repair includes the use of autologous or 
xenographic patches, removal of calcific deposits, or reinforcement of the valve.  Surgery 
can also repair congenital defects of heart valves [72,73].   
If repair cannot sufficiently treat a diseased valve, the next treatment option is 
usually valve replacement.  This therapy typically consists of an open heart surgery, 
including a heart lung bypass machine.  Recent attempts to create minimally invasive 
treatments have resulted in percutaneous valves, which utilize catheterization techniques 
to introduce the valve [74-76].  Replacement valve options include mechanical heart 
valves or bioprosthetic tissue valves.  Some investigation has been made in polymeric 
valves, but they were unsuccessful due to inadequate combination of mechanical 
properties and non-thrombogenicity [77-79].  Attempts mainly included polyurethanes, 
polyesters, and polyethers [77,78].  Polyesters and polyethers degrade under hydrolysis 
and oxidative deamination; polyurethanes were used for their excellent 
hemocompatibility and unique two phase structure.  A large push in research is towards 
the development of tissue engineered heart valves derived from a patient’s own cells [80]. 
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Preexisting conditions and age play a role in choosing optimal valve replacement 
therapy for each patient.  Mechanical heart valves require lifelong systemic anticoagulant 
therapy while bioprosthetic valves do not [72,81].  Patients who cannot tolerate this 
therapy due to blood disorders, pregnancy, or other contraindications should not receive 
mechanical valves [82-86].  Bioprosthetic tissue valves possess a short implant life, so 
they are typically implanted in older patients [7,8].  More about these valve types, their 
selection factors, and shortcomings is discussed in the following section. 
 
1.3 Replacement Heart Valves 
Clinically used prosthetic valves can be broken into two categories: mechanical 
heart valves (MHVs), and bioprosthetic heart valves (BHVs).  Mechanical heart valves 
primarily consist of metal, and have various mechanical designs to improve valve 
performance.  Bioprosthetic heart valves are tissue based and made of either human 
(allograft) or animal-based (xenograft) tissues.  Another treatment option typically used 
in young children is the Ross Procedure [78,87]. The patient’s aortic valve is replaced by 
their pulmonary valve which is in turn replaced by an allograft.  This allows the valve in 
the aortic position to remodel and grow as the patient grows [88].  Recent pushes in the 
field have investigated the use of polymeric heart valves, as well as tissue engineering 
approaches for heart valves [7].  Each type of heart valve has various designs, failure 
modes, advantages, and disadvantages, and will be discussed later in this section. 
A set of design considerations was originally presented by Harken in 1962 [89], 
and has been modernized by Schoen and Levy (Table 1.1) [7].  Ideally, a replacement 
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valve would perform as close to possible as a native valve.  Design considerations 
include mechanical factors, and implant-host factors. Further design factors are ease of 
surgery and patient comfort.  Each valve type tackles some of the design requirements in 
different ways.  For example, mechanical heart valves possess good durability due to the 
use of metal, so altered flow patterns are the design factor that represents the highest 
capacity to improve.  Similarly, tissue valves possess good native hemocompatibility, so 
design changes focus on improving durability and reducing implant calcification. 
Table 1.1 
Desirable Characteristics of a Heart Valve Substitute  
(Adapted from [7]) 
Nonobstructive 
Prompt and complete closure 
Nonthrombogenic 
Infection resistant 
Chemically inert and nonhemolytic 
Long term durability 
Easily and permanently implanted 
Patient-prosthesis interface heals appropriately 
Not annoying to patient 
 
1.3.1 Mechanical Heart Valves 
Mechanical heart valves are composed entirely of synthetic materials, typically 
composed of all metal, or both metal and polymer.  All mechanical valves consist of three 
major parts: sewing ring to attach to the tissue, housing, and occluder.  Flexible fabric 
made of Dacron (polyethylene terephthalate) or ePTFE (expanded 
polytetrafluoroethylene) typically composes the sewing ring to allow attachment to the 
body via sutures.  The housing consists of a base for the sewing ring to attach to, and 
guides the motion of the occluder. The occluder is the only moving part of the valve and 
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it moves to alternately block and allow blood flow.  Mechanical valves exhibit decreased 
hemocompatibility due to their materials and geometry and thus they require lifelong 
anticoagulant therapy.  However these valves also exhibit high durability due to their 
materials properties, which contributes to their low material failure rates.  Therefore 
mechanical valves are typically used for younger patients with long life expectancy.  
These patients must also not have preexisting conditions such as blood disorders or 
pregnancy risk which contraindicate anticoagulant therapy [82,83,86,90]. 
 
1.3.1.1 Types of Mechanical Heart Valves 
Dr Charles Hufnagel designed the first mechanical heart valve, initially implanted 
in 1952. This valve possessed a rather simple design, consisting of a silicone coated 
nylon ball within a methacrylate chamber, implanted in the descending thoracic aorta.  
Rather than a complete replacement, the design of the Hufnagel valve allowed treatment 
of aortic insufficiency and opened the door for future valve replacement designs [72,91]. 
Introduction of the caged ball valve closely followed the Hufnagel valve, 
containing a ball occluder and metal or polymer cage.  The Starr-Edwards caged ball 
valve, introduced in 1961, originally used a silicone ball inside a methyl methacrylate 
cage [72,92,93].  These valves have gone through multiple iterations, substituting 
methacrylate for a metal cage including Stillite-21, and pyrolytic carbon upon its 
discovery.  Modern models utilize a metal, Teflon coated cage and a heat cured silicone 
occluder.  Edwards Lifesciences, Inc. (Irvine, CA) stopped production of these valves in 
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2007 in favor of increased tissue valve development.  By 1998, an estimated 175,000 
patients had received a Starr-Edwards caged-ball valve replacement. 
 
Figure 1.11. Mechanical Heart Valves (A) Hufnagel [72], (B) Starr-Edwards [92], (C) 
Bjork-Shiley [94], (D) Medtronic-Hall [72], (E) St Jude Bileaflet [95]. 
 
The Bjork-Shiley flat tilting disc valve debuted in 1969, comprised of a pair of 
wire retaining struts welded to an orifice, and a disc which would tilt open and closed to 
allow blood flow.  The housing was composed of stellite [91,96], and the disc was made 
of delrin, but delrin was later replaced by pyrolytic carbon [91,97] because the 
hygroscopic nature of the polymer led to changes in the disc shape.  A later model 
replaced the flat disc with a convex-concave disc to improve hemodynamics profiles 
[98]. This improved performance led to implantation in over 100,000 patients [99].  
Multiple iterations of the tilting disc valve have been produced, with changes including: 
B A 
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disc shape (flat versus convex-concave), strut shape, hinge location, and material [81].  
Other common tilting disc valves include the Omniscience valve and the Hall-Kaster 
valve.  The Hall-Kaster valve was renamed the Medtronic-Hall following purchase by 
Medtronic, Inc. (Fridley, MN) in 1987 [72,100-104].  It contained a pyrolytic disc with a 
guidewire hole for ease of implantation.  This design possesses the best performance for 
aortic valve replacement.  Therefore, over 300,000 tilting disc valves have been 
implanted thus far [101,102,105].  
 
Figure 1.12. Evolution of prosthetic heart valves [106]. 
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Four revolutionary bileaflet disc valves were developed from 1960-1986: the 
Gott-Daggett [107], Lillehei-Kalke [108], St Jude Medical bileaflet, and Carbomedics 
bileaflet valves [106,109].  These discs all contain a ring and pair of discs which rotate to 
allow blood flow.  The Gott-Daggett valve contained a polycarbonate ring with a central 
strut, and a pair of Teflon coated silicone discs [107].  Prior to implantation, 
benzalkonium chloride treatment sterilized the valve, followed by a heparin rinse to 
reduce thrombus formation [107].  The goal of this design was profile reduction of the 
device itself.  The other three valve designs are remarkably similar.  They contain no 
central strut and have a pair of discs with struts held in recesses in the housing.  In this 
design the discs are allowed to rotate and provide complete closure.   
 
Figure 1.13. Large scale and small scale models can be combined to give a more 
comprehensive view of blood hemodynamics.  This is particularly useful for hinge and 
leaflet flow regions [106]. 
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The Lillehei-Kalke was composed of titanium, but discontinued quickly due to 
high thrombogenicity [72,108].  Both the St Jude Medical and Carbomedics valves are 
composed of pyrolytic carbon, which is a tough thromboresistant metal.  The St Jude 
Medical bileaflet valve remains the most widely implanted mechanical valve. By 2003 an 
estimated 800,000 were implanted in the aortic position alone [110-112].  Innovation of 
the Carbomedics valve allows complete rotation of the valve within the sewing ring 
housing, enabling optimal surgical placement [72,109].  Further advances in bileaflet 
valves have reduced the profile, altered leaflet designs, and altered hinge designs to 
reduce thrombus formation and provide optimal hemodynamics conditions.  Hinge 
modification ultimately resulted in rolling hinges as in the Edwards MIRA (Edwards 
Lifesciences, Irvine, CA) [113-115], and the elimination of cavity pivots, as in the 
OpenPivot (Medtronic Inc., Fridley, MN) [116].  While mechanical valves are still not 
perfect, they remain the valve of choice for many surgeons.  
 
1.3.1.2 Failure of Mechanical Heart Valves 
Failure of mechanical heart valves can be divided into six types: thrombus-related 
events, anticoagulant-related events, pannus overgrowth, infective endocarditis, patient-
prosthesis mismatch, and structural failure [72,101,117,118].  These failure modes are 
either design-related, or result from host response to the implant.  Many failure modes are 
similar to tissue valves, and are discussed in Sec 1.5.  Design-related failure modes such 
as patient-prosthesis mismatch and structural failure can be mitigated by optimizing 
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design or selecting the proper design for a given patient.  Even pannus overgrowth can be 
mitigated through improvement of sewing rings.   
Host response failure modes such as infective endocarditis, thrombus formation, 
anticoagulant events, and pannus overgrowth can be mitigated through proper clinical 
precautions.  Infective endocarditis and thrombus formation affect the valve similarly to 
native valves.  However, they can progress to cause rejection of the implant and 
inadequate healing at the implant site.  
 
1.3.2 Bioprosthetic Tissue Valves 
Tissue based valves are also called bioprosthetic valves (BHVs), and represent 
approximately half of all valve replacements used clinically.  This number is expected to 
rise as improvements are made and as the patient population ages.  BHVs are derived 
either from human (allograft or autograft) or animal (xenograft) tissue.  These valves are 
superior to mechanical valves due to their reduced thrombogenicity and improved flow 
dynamics, and their lack of long-term anticoagulant therapy.  Overall, BHVs present a 
hemodynamically superior valve.  The thrombus formation rates for BHVs are similar to 
patients receiving mechanical valves and anticoagulant therapy [7]. 
Human tissue valves consist of either allografts or autografts.  An allograft is 
harvested either from organ donors or cadavers, and cryogenically frozen until use 
[117,119-121].  These valves provide near-optimal hemodynamics, but experience 
problems with long term durability.  Cryopreservation consists of using dimethyl 
sulfoxide and liquid nitrogen, and is suspected to inadequately preserve extracellular 
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matrix components [120].  Autografts are most commonly used in children to replace a 
diseased aortic valve with their own functioning pulmonary valve, as in the Ross 
Procedure.  This allows for growth of the valve to accompany that of the patient [117].   
Neither allografts nor autografts require anticoagulant therapy, but structural degradation, 
insufficient long-term durability, and limited availability present major drawbacks for 
these valves [117]. 
Two biologically based materials have been approved for clinical use as 
xenogenic tissue in BHVs: whole porcine aortic valves, and bovine pericardium-based 
valves [7,118,122,123].  Tissue antigenicity must be reduced prior to implantation, and 
can be accomplished through multiple treatments, but glutaraldehyde is the only one 
clinically used.  Glutaraldehyde has the benefit of crosslinking collagen and devitalizing 
cells in the tissue, but results in a tissue possessing inadequate long term durability 
[7,122].  Insufficient space remains for patient cells to populate the implant.  The lack of 
viable cells results in a loss of remodeling capabilities of the valve, and the ECM 
gradually degrades without replacement [20,23,45,124-126].  Two basic parameters can 
be changed in BHVs: chemical treatment and valve design (including mounting, stent 
types, and suturing methods). 
Alternative chemical treatments can reduce negative effects of glutaraldehyde 
crosslinking treatment, while additions to glutaraldehyde treatment may improve tissue 
stabilization.  New chemical treatments should possess many of the benefits of 
glutaraldehyde, including reduced immunogenicity.  They should also show improved or 
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similar mechanical properties, and mainly aim to improve enzyme resistance or reduce 
calcification.  These treatments will be further discussed in Sections 1.4, 1.6, and 1.7. 
  
  
Figure 1.14. Tissue heart valves (A) Carpentier-Edwardss PERIMOUNT Magnas 
Pericardial Bioprosthesis (Stented) [8], (B) Edwards Prima Pluss Stentless Bioprosthesis 
[8], (C) Edwards Sapien Pericardial Percutaneous Valve [75], (D-E) CoreValve 
Percutaneous Valve [75]. 
 
BHVs are designed to be either stented or stentless (Figure 1.14).  Stents are made 
from artificial material, either metal or plastic, and covered in a fabric sewing ring to 
B A 
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provide a frame for the valve.  Stentless BHVs allow for implantation of larger valves, 
yielding increased implant performance [7,8,122,127]. 
Early stented valves used rigid metal stents with three posts (Figure 1.14).  These 
valves exhibited a high failure rate due to tears at commissures near the posts.  The 
concept of a flexible stent to reduce the rigidity of the frame was pursued to alleviate 
stress in the tissue near the posts.  Initial attempts were unsuccessful at mitigating this 
failure, and introduced further deformation problems.  Modern stents utilize a flexible 
polymer-based stent, contributing improved mechanical properties to mitigate this failure 
mode.  Stents also increase the ease of valve implantation procedures.  Expandable metal 
stents, similar to those used in the vasculature, are of recent interest for use with 
percutaneous intracatheter delivered valves [74-76,78]. 
While the increased size of stentless valves allows better approximation of a 
patient’s normal valve, their design lacks some of the benefits which stented valves 
present for implantation.  For example, this design contains additional xenogenic aortic 
wall material [7,122].  This increases the chance for calcification and pannus overgrowth 
in the valve, as well as inadequate implant integration [7].  Additionally, their design 
increases the level of difficulty of implantation, and therefore limits the operation to more 
experienced and skilled surgeons [122]. 
Porcine aortic valves and bovine pericardium remain the only two xenogenic 
materials used for BHVs.  Porcine vena cava has also been investigated as an alternative 
to bovine pericardium, with promising initial results [123].  The anatomical structure of 
porcine valves is highly similar to human valves, but two main differences exist.  Porcine 
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valves contain a muscle shelf to support the right coronary cusp, and also possess less 
fibrous continuity between the mitral and aortic valve [122,127,128].  This shelf is an 
extension of the ventricular septum, and may promote calcification and reduce valve 
range of motion [7,122,127,128].  To eliminate this shelf in the valve, some 
manufacturers elect to select optimal leaflets, treat them individually, and match them for 
appropriate size prior to assembly [7,122,127].  Pericardial valves are formed from sheets 
of pericardium, which are cut and constructed to form a trileaflet valve [7,8,122].   
The structure of pericardium is different from the structure of valve cusps.  The 
pericardium contains a smooth inner layer, middle fibrosa layer, and an outer rough layer 
[7,123].  The rough layer contains collagen and elastin which must be trimmed from 
desired tissue to present a more uniform surface.  This surface is still rough, so it 
becomes the inflow surface which allows for washing of the surface to prevent thrombus 
formation.  The fibrosa contains collagen, elastin, microvessels, and nerve bundles.  
Pericardial based valves allow for optimization of design for improved hemodynamics, 
but their vastly different structure imparts inferior biomechanics for durability 
[122,127,129]. 
Bioprosthetic valves suffer from various failure modes.  Some failure modes can 
be alleviated through improved design and chemical fixation, but other patient specific 
failure modes cannot be sufficiently mitigated.  Failure modes of BHVs will be further 
discussed in Section 1.5 
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1.4 Tissue Fixation Methods 
Fixation methods are chemical treatments, applied to xenogenic bioprosthetic 
valve tissue.  Utilization of these treatments accomplishes three things: it sterilizes the 
tissue prior to implantation, renders the tissue inert (reduce antigenicity) to reduce 
immune rejection, and stabilizes the extracellular matrix since remodeling is not possible.  
Stabilization of collagen, elastin, and GAGs in the extracellular matrix is necessary to 
provide mechanical integrity for long term application.  Chemicals for fixation need to 
create irreversible and stable crosslinking bonds between various tissue components.  
These bonds can be created by binding to carboxyl groups and various amino acids 
within the tissue in order to increase its stability. 
 
Figure 1.15. Glutaraldehyde (A) monomer structure free polymerizes in ring form and 
(B) schematic of reaction with collagen [130]. 
 
Early bioprosthetic valves used formaldehyde to provide adequate stability.  
However, the bonds were found to be reversible, so long-term durability remained a 
concern.  With the advent of glutaraldehyde in 1969, formaldehyde treatment was 
replaced permanently.  Glutaraldehyde remains the primary clinically used fixative due to 
B A 
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its proven advantages.  It is cheap and readily soluble, though may have some harmful 
effects to the body due to reactivity concerns.  Glutaraldehyde’s IUPAC name is 1,5-
pentanedialdehyde, and its most stable form is a bifunctional five carbon aldehyde.  In 
aqueous solution, glutaraldehyde can occur as a free aldehyde, monohydrate, dihydrate, 
hemiacetal, or any polymerized form (Figure 1.15).  BHVs are treated initially with low 
concentration glutaraldehyde for 24 hours in order to optimize fixation. 
Two different reactions occur between glutaraldehyde and tissue which are 
important in tissue fixation: Aldol condensation and Schiff bases.  Aldol condensation 
can occur between two aldehyde groups, yielding unsaturated (unless each end is bound) 
polymerized glutaraldehyde.  Schiff base bonds form with lysine or hydroxylysine 
residues in collagen, and can bind two collagen molecules together. Glutaraldehyde also 
reacts with carboxyl and amide groups in proteins.  It reacts most preferentially with 
primary amines and least preferentially with hydroxyls.  Low concentrations of 
glutaraldehyde allow adequate penetration into the tissue for maximum fixation potential, 
in contrast to high concentrations which quickly create less permeable surface crosslinks. 
Glutaraldehyde presents several benefits over formaldehyde crosslinking.  First, 
formaldehyde is a reversible fixation process, and can only react with one collagen 
molecule.  Treatment with formaldehyde results in cusp stretching, deformations, and 
increased immune response.  Even though it presents benefits over formaldehyde, 
glutaraldehyde has its own problems.  Glutaraldehyde is known to depolymerize and 
release byproducts into the surrounding environment.  Residual glutaraldehyde 
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exacerbates calcification in vivo, and crosslinking fails to block calcium nucleation sites.  
This causes the tissue to stiffen and undergo further mechanical damage. 
Residual glutaraldehyde, unreacted in crosslinked tissue, can also cause 
inflammatory or cytotoxic responses, as well as promote calcification [131-134].  
Glutaraldehyde cytotoxicity hinders cellular ingrowth, reducing macrophage activity, and 
the attachment of native endothelial cells.  Cytotoxicity can be reduced by thoroughly 
rinsing the implant in saline prior to implantation.  Glutaraldehyde’s pro-calcific effects 
can be neutralized or reduced by various anticalcification treatments.  Amino oleic acid 
(AOA) neutralizes glutaraldehyde by using amino groups to sequester free aldehydes, 
allowing endothelial growth and mitigating calcification. 
Alternative fixation chemistries are constantly being investigated.  To name a 
few, fixation chemistries include: epoxies, acyl azides [135], polyethylene glycol 
[136,137], quercetin [138], carbodiimide [28,139-144], periodate [142,145], 
triglycidylamine [135], and dye mediated photo oxidation [134,146].  It is hoped that 
properties of these fixation chemistries can help solve the issues experienced by 
glutaraldehyde treated tissue.  Carbodiimide and epoxy-based chemistry have entered 
clinical trials.  Carbodiimide treatment is further discussed in section 1.6 in regards to 
GAG stabilization.  Use of epoxies as a fixative yields increased pliability and a more 
pleasing appearance of valves.  Triglycidylamine is one such polyepoxide, which is being 
investigated for use in porcine aortic cusps, bovine pericardium, and collagen fixation.  
Characterization showed similar shrinkage temperatures to glutaraldehyde, increased 
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collagenase resistance in vitro, improved mechanical properties, and decreased 
calcification levels were seen in subdermal implants [135]. 
Additions to glutaraldehyde are also being investigated and used clinically.  One 
such calcification reduction method is used in Linx™ technology (St Jude Medical, St 
Paul, MN).  Ethanol preincubation reduces calcification potential in valve leaflets 
through the removal of phospholipids and cell debris as well as causing conformational 
changes in collagen [133,147].  Ethanol has shown marked reduction in collagen related 
and cell initiated calcification, but fails to reduce elastin-mediated calcification.  
Additional investigations into mitigating elastin-mediated calcification could prove 
beneficial. 
Multiple fixation additions to glutaraldehyde or altered fixation methods have 
been investigated to preserve glycosaminoglycans.  Carbodiimide crosslinking, neomycin 
incorporation, and periodate oxidation are such methods which have previously shown 
promise, and are discussed in more depth in section 1.6. 
In short, glutaraldehyde is clinically used to chemically crosslink tissue heart 
valves, but it presents its own shortcomings.  These can be overcome by developing new 
crosslinking technology to increase stability of tissue against structural degradation and 
calcification.  Many promising techniques exist, but proving their efficacy is a lengthy 
process, and after several years of investigation, failure in clinical trials remains a 
possibility. 
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1.5 Bioprosthetic Valve Failure 
Currently, marketed BHVs employ glutaraldehyde treated tissue.  The resulting 
tissue is adequate for application, but rather suboptimal in long term performance.  
Roughly half of these valves fail within 12-15 years [7,117].  BHVs fail along four 
different paths: endocarditis, thromboembolism, non-structural dysfunction, and 
structural degradation [7,54,59,60,62,117,122,124,148-152].   
 
1.5.1 Endocarditis 
Infective endocarditis incidence is dependent on sterility and the skill of the 
surgeon [58-62,151,153,154].  The progression of endocarditis is similar in BHVs and 
native heart valves, but is more common to present early on in the implant life.  
Organisms commonly infecting valves include Staphylococcus aureus, Staphylococcus 
epidermidis, Streptococcus pneumoniae, and Aspergillus.  Early diagnosis can utilize 
antibiotic treatments, but disease progression can result in valve failure.  The most 
common mode of failure associated with endocarditic prostheses is dehiscence, or the 
detachment of the implant from the suture line.  Frequency of failure can be limited by 
maintaining surgical sterility.  Future attempts to limit could include antibacterial 
coatings of sewing rings, similar to those being investigated for vascular grafts. 
  
1.5.2 Thromboembolism in BHVs 
While BHVs have a reduced risk for thrombosis in comparison to mechanical 
valves, the risk remains, particularly early on following implantation.  Although tissue-
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derived leaflets already possess thromboresistant material, they must go through an 
adaptation period following implantation.  Thromboembolism risk is still high for 
approximately three months post-operation due to incomplete integration of the implant 
with native tissue.  Consequently, anticoagulants are administered during this time 
period.  Due to artificial materials and altered hemodynamics, stented valves have a 
slightly higher risk of thromboembolism than stentless valves.   
 
1.5.3 Non-structural dysfunction in BHVs 
Non-structural dysfunction encompasses host responses to BHVs, including 
pannus overgrowth, hemolysis, and paravalvular leakage.  These complications, pannus 
overgrowth in particular, occur at similar rates across implant types.  Pannus overgrowth 
of tissue extends over the sewing ring during integration, and can spread to affect the 
motion of valve cusps, eventually inhibiting their ability to open and close [155]. 
Hemolysis is caused by shear forces on blood cells, and typically occurs on the 
surface of valves.  Hemodynamics performance affects hemolysis rates, and can be 
altered by design type.  The Reynolds number is a measure of the ratio of inertial to 
viscous forces, and can be used as a parameter for predicting hemolysis.  Since tissue 
valves have more natural leaflet action than mechanical valves, better flow profiles occur 
and result in decreased blood shear and hemolysis. 
Paravalvular leakage is typically preceded by valvular endocarditis, and consists 
of leakage at the interface of the valve to the patient’s tissue.  It allows blood to flow 
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around the implant and to circumvent the valve when closed.  This results in undesired 
backflow and inferior hemodynamic performance. 
  
  
Figure 1.16. Bioprosthetic heart valve failure. (A) Removed porcine BHV from mitral 
position for 8 years. Tears and calcific nodules can be seen [117]. (B) Porcine BHV from 
mitral position, implanted for 7 years.  Prosthesis shows thickening of cusps and white 
vegetations from infection [117].  (C) Aortic surface of explanted BHV showing two torn 
cusps with prolapse [156]. (D) Left ventricular outflow surface shows a torn cusp and 
extensive pannus formation covering portions of the cusps [156]. 
 
B A 
C D 
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1.5.4 Structural degradation in BHVs 
Structural degradation remains the primary mode of failure for BHVs, and 
includes calcific and noncalcific degradation [7,117,157].  Noncalcific structural 
degradation involves mechanical and material based degradation which does not involve 
mineralization of the cusps, while calcific degradation involves deposition of mineralized 
calcium phosphate crystals in tissue to create calcific nodules.  Cusp calcification 
typically results in leaflet hardening and stenosis.  Reduction in rates of these failure 
modes may be accomplished through improved chemical fixation modalities. 
Roughly 75% of all porcine aortic valves experience structural degradation such 
as cusp tears [7].  This usually presents as valvular insufficiency. In vivo factors such as 
mechanical forces and enzymatic digestion initiate degradation of the extracellular 
matrix.  Since fixed tissue loses its ability to remodel and innate enzyme resistance, the 
proteins are slowly degraded, which exacerbates mechanical fatigue.  Chemical 
treatments of BHV material cause microscopic changes to the tissue, which can increase 
stiffness or cause localized stresses.  Mechanical failure usually results in cusp tears or 
buckling of the tissue. 
Treatment with glutaraldehyde is known to cause two changes contributing to 
degradation: crosslinking of collagen and loss of cell viability [7].  Tissue begins 
deteriorating immediately following harvesting and cell death causes the release of ECM 
degrading proteases [20,23,45,125].  The loss of extracellular matrix components, in 
particular collagen damage and loss of GAGs, has been observed following fixation and 
in explanted valves [20,23,125,141,142,144,158,159].  Insufficient stabilization against 
 45 
enzymes can have drastic effects on the integrity of the ECM and durability of tissue 
valves in vivo [45,160].  Glutaraldehyde crosslinking of collagen accomplishes a fair 
degree of extracellular matrix stabilization, but at the cost of flexibility [7].  Crosslinks 
and stabilization result in a locked configuration characterized by increased cusp rigidity 
with increased localized stresses [131,161,162].  Inability of glutaraldehyde to adequately 
preserve GAGs promotes tissue stresses and susceptibility to mechanical damage 
[7,20,124,143,163]. 
Calcification pathways are not fully understood, but are affected by various 
factors including tissue damage, host response, and material [7,157].  Calcification begins 
with initiation or nucleation of crystals within the tissue itself.  These crystals propagate, 
resulting in a deteriorated structure and increased stiffness.  Thus, calcification has a 
direct effect on structural integrity and long term durability of BHVs.  Due to higher 
metabolic rates, calcification progresses quicker in younger patients, resulting in faster 
failure of BHVs than in older patients.   
In living tissue, cells contain ion pumps to regulate calcium levels, but following 
cell death this ability is lost [7,51,125,157,164,165].  Consequently, any calcium influx 
cannot be removed, allowing high concentrations of calcium to build up within cells.  
Calcium reacts with intracellular phosphorous from organelles, nucleic acids, and 
membrane components which results in nucleation and initiation of mineralization within 
residual cells [157].  Additional nucleation sites may also be present in the extracellular 
matrix.  Elastin mediated calcification occurs without chemical crosslinking of the tissue, 
but collagen crosslinking with glutaraldehyde creates nucleation sites [166].  Theories 
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suggest that elastin is normally protected by glycoproteins and microfibrils, which are 
lost during tissue preparation or matrix metalloproteinase (MMP) activity, allowing 
calcification to begin.  GAGs are theorized to inherently inhibit calcium through 
chelation or steric hindrance [125].  In vivo rat subdermal implantation models have 
shown that GAG loss promotes calcification, while GAG stabilization inhibits 
calcification [145,158,162,167]. 
 
Figure 1.17. Model for structural dysfunction in bioprosthetic heart valves.  Two 
pathways are shown, one induced by stress, resulting in structural degeneration and valve 
failure.  The other is affected by implant and host factors, results in cuspal calcification 
and valve failure.  Implant and host factors induce collagen-oriented deposits, seen in the 
ultrastructure, and predominate at flexion points and commissures. The pathways are not 
independent, however, since structural degeneration predisposes cusps to calcification 
[7].   
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Even after forty years of clinical use and development, structural degradation 
remains a problem in BHVs.  Extracellular matrix loss exacerbates degradation and 
calcification of tissue.  Additions or alterations to current chemical treatments may prove 
beneficial to reducing structural degradation, improving durability, and increasing the life 
of bioprosthetic heart valves. 
 
1.6 GAG Loss and Prevention in Bioprosthetic Heart Valves 
Glycosaminoglycans (GAGs) are a critical component of the undiseased native 
valve.  Their primary role is to reduce shear stresses and maintain flexibility of the valve 
leaflet.  Glutaraldehyde is the standard chemical treatment for bioprosthetic valve tissue, 
which stabilizes collagen but fails to stabilize GAGs, because GAGs lack amine residues 
necessary for glutaraldehyde crosslinking.  Degradation of extracellular matrix 
components is initiated following tissue harvesting [125].  Consequently, GAGs are lost 
during preparation for fixation.  Since they are not stabilized following glutaraldehyde 
fixation, they are also lost during storage, cyclic fatigue, and implantation 
[20,23,28,124,141,142,144,159].  Studies have shown that higher levels of GAGs 
generally result in lower calcification levels and that GAG loss has indirectly been linked 
to calcification in subdermal implants.  Therefore, it is theorized that the loss of GAGs 
contributes to both calcification and structural degradation of BHVs. 
GAG loss is also thought to cause significant changes to tissue biomechanics. 
Loss of GAGs within the spongiosa results in increased shear stresses and leaflet rigidity.  
 48 
Increased stiffness results in higher compressive forces during leaflet flexure, and GAG 
loss has been shown to result in increased degrees of tissue buckling [143,158]. 
In efforts to increase valve durability, GAG stabilization fixation strategies have 
been attempted.  The goal is to minimize preparation time, and either supplement 
glutaraldehyde crosslinking or completely replace it with a more efficient crosslinking 
modality.  To test this, GAG stability is evaluated following fatigue, implantation, and 
storage.  Sodium metaperiodate and carbodiimide crosslinking have been investigated as 
replacements for glutaraldehyde crosslinking, while neomycin has been investigated to 
supplement both glutaraldehyde and carbodiimide crosslinking in efforts to stabilize 
GAGs [20,28,123,139-145,158,159]. 
Sodium metaperiodate crosslinking focused on using the periodate ion to activate 
diols within hyaluronic acid to aldehyde groups, allowing reactions with lysyl amine 
groups and other molecules within tissue [20,142,145].  It also creates collagen crosslinks 
within the extracellular matrix.  Comparisons of periodate to glutaraldehyde treatment 
showed both an increase in GAGs within the tissue, and reduced calcification in a 21 day 
subdermal model.  Studies also showed higher GAG stability against enzymatic 
degradation and long-term calcification reduction.  However, further increases to GAG 
stability could prove more beneficial. 
Carbodiimide crosslinking uses EDC (1-ethyl-3-3-dimethylaminopropyl 
carbodiimide) and NHS (N-hydroxysuccinimide) to create crosslinks [28,141-144].  EDC 
activates the GAG carboxyl groups, and NHS forms a stable intermediate.  This complex 
acts as a transfer agent, and forms amide bonds with free collagen amine groups.  
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Stability of GAGs in the tissue has been repeatedly shown to be more effective when 
carbodiimide treatment supplements glutaraldehyde than glutaraldehyde crosslinking 
alone.  When used alone, carbodiimide still fails to adequately stabilize GAGs against 
enzymatic degradation. 
 
 
Figure 1.18.  (A) Neomycin trisulfate (www.drugs.com), (B) reaction of carbodiimide 
and collagen, activated by NHS [168]. 
 
Neomycin is a hyaluronidase inhibitor which contains multiple amine 
functionalities which can supplement multiple crosslinking modalities 
[28,141,143,144,158,159].  Enzymatic GAG degradation is inhibited both by blocking 
active cleavage sites and direct binding to hyaluronidase.  Its unique combination of 
hydrophilic and lipophilic residues allows steric hindrance of the active site of 
hyaluronidase, causing conformational changes to inactivate the enzyme.  Neomycin 
A 
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alone does not adequately preserve GAGs, but its crosslinking must be initiated using 
crosslinking modalities such as glutaraldehyde and carbodiimide. 
When used in conjunction with either glutaraldehyde crosslinking or carbodiimide 
crosslinking, neomycin has shown promising ability to protect GAGs against cyclic 
fatigue and storage for up to 6 months [28,141,143,144,158,159].  The combination of 
carbodiimide and glutaraldehyde crosslinking was also used.  Successful preservation of 
GAGs resulted in reduced tissue buckling, and slightly increased collagen and elastin 
stability.  Neomycin incorporation may contribute to better ECM stability, thus 
increasing BHV durability and helping stave off structural damage and failure. 
 
1.7 Elastin Preservation  
Elastin is generally perceived as degradation resistant, owing to its insolubility, 
intrafibrillar crosslinks, and low biological turnover rate.  However, a variety of enzymes 
are capable of degrading elastin.  Hydrophobic domains are susceptible to pancreatic 
elastase, neutrophil elastase, and matrix metalloproteinases (MMP-2, MMP-9, and MMP-
12) [39,44-46,169-173].  Matrix metalloproteinases have been shown to be active in 
diseased heart valves, as well as explanted heart valves and aortic aneurysms [44,169].  
Elastin degradation in the vasculature results in the release of elastin peptides which 
increase expression of elastin laminin receptor, and synthesis of MMPs.  These peptide 
fragments have further effect on other cell types, including activating immunological 
cells, and activating smooth muscle cells to a proliferative phenotype [174-179].  It is 
unclear whether the release of elastin peptides from xenogenic heart valves would result 
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in similar upregulation in areas further down the bloodstream, but elastin degradation 
does remain an issue in structural degradation and durability of BHVs. 
 
 
 
Figure 1.19.  Mechanism of tannic acid and PGG crosslinking.  (A) Structural domains 
of elastin, demonstrating repeat units of α-helix hydrophilic domains and β-strand 
hydrophobic domains.  Elastin is naturally crosslinked by desmosine crosslinks, indicated 
by –X – [126]. (B) Hypothetical interactions between tannic acid and elastin, comprised 
of (1) hydrophilic crosslinks, (2) hydrophobic domains, (3) natural desmosine crosslinks, 
(4) tannic acid core incorporated into hydrophobic areas, and (5) hydrogen bonds 
between elastin and tannin hydroxyl residues [180] 
 
A 
B 
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Figure 1.20.  Chemical structure of tannic acid and pentagalloyl glucose.  Tannic acid is 
a deca-galloyl glucose containing a central glucose molecule and two gallic acid 
molecules bound by ester bonds to each glucose hydroxyl residue.  Pentagalloyl glucose 
is highlighted by the shaded circle, and one gallic acid molecule at each glucose hydroxyl 
residue, thus reducing the number of hydrolysable ester bonds [181]. 
 
Tannins such as tannic acid and pentagalloyl glucose (PGG) were previously 
shown to stabilize both pure elastin and the aortic wall against elasteolytic degradation 
[126,180-183].  These tannins are derived from plant polyphenols.  They possess a 
central glucose molecule, and a chain of gallic acid residues containing high levels of 
phenolic hydroxyl groups.  PGG contains one gallic acid group per chain, while other 
tannins possess longer chains.  These molecules are able to specifically bind to proline 
rich hydrophobic regions in elastin and collagen, forming multiple hydrogen bonds with 
surrounding proteins.  Studies have shown these bonds are partially reversible in PGG 
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and glutaraldehyde treated tissue, but are still more effective than glutaraldehyde 
crosslinking alone at resisting elastase digestion following leaching testing.  Elastin 
stabilization utilizing PGG and a reduction of calcification in comparison to 
glutaraldehyde have both been demonstrated in vivo and thought to be directly caused by 
the preservation of elastin [181]. 
Previous studies demonstrated that concentrations of PGG used in conjunction 
with glutaraldehyde treated aortic wall are not cytotoxic to rat skin fibroblasts [181,183].  
They also showed the hydroxyl groups are essential to the elastin stabilizing ability of 
PGG.  However, PGG incorporation in elastin rich aortic wall resulted in stiffer and less 
distensible tissue than either fresh or glutaraldehyde treated tissue. 
No previous studies have investigated elastin stabilization in porcine aortic cusps.  
Additionally, no previous studies utilized porcine aortic cusps and PGG incorporation 
into glutaraldehyde crosslinking.  Valve mechanics, durability, and resistance to 
calcification may be improved by stabilizing elastin against degradation, but elastin 
stabilizing needs further study.  Previous studies point to the fact that PGG may be a 
solution to improving the durability of bioprosthetic heart valve cusps. 
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CHAPTER TWO 
PROJECT RATIONALE 
2.1 Overview 
Since the advent of glutaraldehyde crosslinked bioprosthetic heart valves in the 
1970s, only small changes have been made to crosslinking modalities to improve their 
performance.  Durability remains the primary issue with bioprosthetic heart valves 
(BHV), the majority of which fail within 12-15 years post-implantation.  This expected 
implant life limits the use of bioprosthetic valves to elderly patients or patients who 
cannot tolerate anticoagulant therapy required in mechanical valves.  BHVs are normally 
contraindicated in younger patients due to expected implant life in order to limit 
reoperation procedures.  Valve dysfunction may lead to death or reoperation in elderly 
patients.  Failure rates and life expectancy of both groups of patients with BHVs may be 
improved with increased durability. 
In order to improve the durability of BHVs, rates of failure need to be reduced for 
the two primary failure modes: structural degradation and calcification.  Glutaraldehyde 
crosslinking is suspected to play a role in both failures modes.  Various replacements or 
modifications to glutaraldehyde crosslinking recently investigated still fail to provide 
optimal results.  Many approaches aim to reduce calcification, but these may fail to 
sufficiently stabilize the extracellular matrix to provide optimal mechanics or resistance 
to enzymes in vivo.  The development of further strategies to stabilize the extracellular 
matrix to reduce degradation due to fatigue or enzymes, and complement calcification 
reduction treatments may provide an optimal valve tissue. 
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Structural degradation is highly dependent on mechanics.  Crosslinked tissues 
lack living cells necessary for repairing normal tissue damage associated with fatigue and 
turnover.  Glutaraldehyde crosslinking does not crosslink GAGs, which play a key role in 
stress distribution, flexibility, and buckling resistance, and leach out of the tissue over 
time during implantation, storage, and fatigue.  Loss of GAGs over time may directly 
affect collagen integrity.  Glutaraldehyde is known to crosslink collagen well, but has 
little effect on elastin.  Though it is too large to leach as GAGs do, elastin may still be 
susceptible to elastin degrading enzymes, yielding fragments affecting biomechanics and 
calcification.  Elastin’s suspected role in valve tissue biomechanics has been documented, 
and may also affect collagen integrity, leading to tears and failure. 
 Neomycin has previously been shown to preserve GAGs in porcine aortic valves 
when combined with glutaraldehyde and with carbodiimide crosslinking, as well as in 
porcine vena cava and bovine pericardium when combined with glutaraldehyde 
crosslinking.  Neomycin is a hyaluronidase inhibitor which may prevent GAG 
degradation.  It is incorporated into the tissue via its multiple amine groups, which 
crosslink with the tissue during glutaraldehyde or carbodiimide fixation.  Pentagalloyl 
glucose has previously been shown to stabilize elastin in porcine aortic wall, pure elastin, 
and abdominal aortic aneurysm in rats.  Polyphenolic hydroxyl groups in PGG play a key 
role in crosslinking, but synergistic methods between PGG and glutaraldehyde are not 
fully understood; binding may occur at different sites, or PGG and glutaraldehyde may 
react to form better chemical crosslinkers such as acetals. 
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The combination of neomycin and carbodiimide crosslinking has previously been 
shown to preserve GAGs in short term storage in formalin and in vivo studies.  Long term 
application and optimization of fixation methods will be used to demonstrate its viability 
for use in a functional model. 
 We hypothesize that through combining neomycin’s GAG-preserving properties 
and PGG’s elastin preserving properties, a valve tissue can be created which incorporates 
these properties with glutaraldehyde crosslinking.  Further use of ethanol will prevent 
tissue calcification. 
 
2.2 Research Aims 
Aim 1: Evaluate the effect of each fixation step on GAG stabilization when using 
neomycin and carbodiimide crosslinking with isopropanol storage and ethanol 
treatment. 
Additional insight into reaction chemistry can be gained by evaluating which 
fixation step are critical to preserving GAGs and improving GAG stability against 
enzymatic degradation.  This will be evaluated by removing several samples at each 
solution change, exposing to GAG-degrading enzymes, and measuring tissue GAG 
levels.  Investigation into which fixation step is most essential could be beneficial for 
future studies incorporating other chemicals, and indicate to future researchers which 
steps need additional optimization. 
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Aim 2: Assess the long term in vivo and storage properties of porcine aortic cusps 
crosslinked with neomycin and carbodiimide modalities. 
Previous studies using neomycin and carbodiimide crosslinking have investigated 
short term (21 day) subdermal studies in juvenile rats.  These studies induce rapid 
calcification and degradation equivalent to multiple years of in vivo use clinically.  In 
order to evaluate the performance of the crosslinked valves in increasing implant life, 
longer term studies need to be performed.  Therefore, 10 week and 15 week implant 
studies will be performed in order to evaluate the ability of neomycin and carbodiimide 
crosslinking to reduce calcification and GAG loss in vivo. 
Further, porcine aortic valves typically have shelf lives of two years following 
manufacture.  It is therefore necessary to evaluate the stability of valves following storage 
in solution.  Isopropanol in HEPES buffered saline is used for storage, as toxicity is lower 
than formaldehyde or glutaraldehyde, and is should demonstrate similar effect.  Valves 
will be stored for ten months, after which GAG loss, elastin stabilization, and collagen 
stabilization will be evaluated. 
 
Aim 3: Develop the optimal concentration of pentagalloyl glucose used in 
crosslinking for preserving elastin. 
Pentagalloyl glucose (PGG) is a polyphenol which has previously been used to 
stabilize elastin in aneurysm treatment, and in porcine aortic wall.  Since porcine aortic 
cusps have not been tested for crosslinking using PGG, the optimal concentration of PGG 
for crosslinking elastin, collagen, and preserving GAGs will be evaluated.  Fixation will 
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be performed both with and without neomycin trisulfate in order to evaluate the efficacy 
of combining these treatments. 
 
Aim 4: Evaluate the effect of neomycin and PGG crosslinking on cusp material 
properties, and their performance in an in vivo subdermal calcification model. 
Additional crosslinking can change material properties and alter in vivo 
chemistries.  PGG creates additional crosslinks to preserve elastin, which is essential to 
valve mechanics and can play a role in valve calcification.  To investigate material 
properties, tensile testing will be used to evaluate elastic moduli, strength, and 
extensibility.  Differential scanning calorimetry will be used to measure thermal 
denaturation temperature, and used in conjunction with the change in elastic moduli to 
demonstrate the formation of additional crosslinks. 
A short term in vivo rat subdermal model will demonstrate the efficacy of 
combining neomycin, PGG, glutaraldehyde, and ethanol treatments in reducing 
calcification and GAG loss while increasing resistance to elastin and collagen degrading 
enzymes. 
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CHAPTER THREE 
GAG STABILIZATION USING NEOMYCIN AND CARBODIIMIDE 
MEDIATED CROSSLINKING 
3.1 Introduction 
 Tissue preservation methods have been used to treat xenogenic tissue for 
bioprosthetic heart valve application for decades.  Glutaraldehyde remains the industry 
standard for preserving tissue, due to its ability to reduce immunogenicity by devitalizing 
cells and crosslink collagen.  Collagen crosslinking improves durability and prevents 
enzymatic degradation.  Though it has its benefits, glutaraldehyde is toxic if it leaches 
from the implant, and is also implicated in calcification roles.  The increased stiffness of 
glutaraldehyde crosslinked tissue also may result in less distensible tissue which fails 
early due to structural degradation. 
 Glutaraldehyde also fails to stabilize glycosaminoglycans (GAGs), which are 
thought to play a role in shock dissipation, and shear stress reduction between valve 
layers.  These molecules leach and are degraded by enzymes in vivo, and cannot be 
replenished since living cells do not populate BHVs.  Neomycin has been used to 
stabilize GAGs and prevent enzymatic degradation, when utilizing both glutaraldehyde 
crosslinking and carbodiimide crosslinking.  Carbodiimide crosslinking presents a new 
crosslinking modality which may result in improved material properties.  The use of 
neomycin and carbodiimide crosslinking without glutaraldehyde treatment was 
previously shown to stabilize GAGs in the extracellular matrix.  The previous study only 
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examined short term applications, however.  This study will focus on the ability of 
neomycin and carbodiimide crosslinking to preserve GAGs in long term applications. 
 In order to increase understanding of the fixation process, GAG stability was 
analyzed at different steps in the fixation process.  Long term subdermal models of 10 
and 15 weeks in juvenile rats were used to evaluate GAG stability and content, as well as 
any calcification reduction potential of the new treatment.  Valve leaflets were also stored 
for 10 months in storage solution.  Following storage, they were examined for GAG 
content and resistance to enzymatic degradation of GAGs, elastin, and collagen. 
 
3.2 Methods 
3.2.1 Materials 
 Sodium chloride, hydrochloric acid, acetyl acetone, calcium chloride, sodium 
azide, isopropyl alcohol, glycine and dibasic sodium phosphate were purchased from 
Fisher Scientific (Fair Lawn, NJ).  Collagenase (VII) from Clostridium histolyticum, 
chondroitinase ABC from Proteus vulgaris, hyaluronidase from bovine testes, 
ammonium acetate, neomycin trisulfate, 1,9-dimethylmethylene blue, D(+) –
Glucosamine, and chondroitin sulfate C salt were purchased from Sigma-Aldrich 
Corporation (St Louis, MO).  Porcine pancreatic elastase was purchased from Elastin 
Products Co (Owensville, MO).  8% EM grade glutaraldehyde was purchased from 
Polysciences, Inc. (Warrington, PA).  Sodium chloride, sodium carbonate, N-
hydroxysuccinimide, and ethylene diamine tetraacetic salt were purchased from Acros 
Organics (Morris Plains, NJ).  Ultrex II hydrochloric acid and 2-(N-morpholino) 
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ethanesulfonic salt were purchased from J.T. Baker (Phillipsburg, NJ).  P-dimethyl 
aminobenzaldehyde was purchased from Ricca Chemical Co. (Arlington, TX).  ACS 
grade Ethanol was supplied from Pharmaco-Aaper (Shelbyville, KY).  4-(2-
hydroxyethyl)-1-piperazinesulfonic acid (HEPES) was purchased from EMD Chemicals 
(Billerica, MA).  Lanthanum oxide (III) was purchased from Alfa Aesar (Ward Hill, 
MA). 1-ethyl-3-(3-dimethylaminopropyl) carbodiimide was purchased from Creosalus 
Pharmaceutical (Louisville, KY).  Porcine aortic valves were supplied from Snow Creek 
Meat Processing (Seneca, SC). 
 
3.2.2 Tissue Preparation and Fixation 
 Fresh porcine aortic valves were harvested on site at a local slaughterhouse, Snow 
Creek Meat Processing (Seneca, SC). Valves were excised immediately upon animal 
death, and were removed by incisions just below the aortic cusps, and above the aortic 
sinuses. The valves were transported on ice back to the laboratory, and were thoroughly 
rinsed in 0.9% saline.  Excess muscle tissue, fat, and aortic wall was removed from the 
valve, leaving approximately 2 cm of aortic wall connected to the leaflet.  Following 
rinsing and trimming, whole valves were fixed; or the three cusps were separated by 
cutting along the aortic wall, and fixed immediately.  All fixation steps used 33 ml 
solution per cusp, and carried out at room temperature within four hours of harvesting. 
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GLUT:  Tissue was placed in 0.6% glutaraldehyde in 50 mM HEPES buffered saline 
(pH 7.4) for 24 hours, solution decanted, and replaced with 0.2% glutaraldehyde in 50 
mM HEPES buffered saline (pH 7.4) for at least six days. 
 
NCIE: Tissue was placed in 0.5 mM neomycin trisulfate in 50 mM MES buffered saline 
(pH 5.5) for one hour under constant orbital shaking.  Solution was decanted and replaced 
with 30 mM 1-ethyl-3-(3-dimethylaminopropyl) carbodiimide (EDC) and 6 mM N-
hydroxysuccinimide (NHS) in 50 mM MES buffered saline (pH 5.5) for twenty-four 
hours.  Following fixation, valves were placed in 20% isopropanol in 50 mM HEPES 
buffer (pH 7.4) for at least six days. 
 
3.2.3 Enzymatic Stability of GAGs 
Aortic valve leaflets were carefully excised from the aortic wall, and washed 
thoroughly in 100 mM ammonium acetate buffer (AAB) at pH 7.0 3x for 5 minutes.  
Leaflets were cut symmetrically, one half incubated in 1.2 mL GAG degrading enzyme 
solution (5 U/mL hyaluronidase, 0.1 U/mL chondroitinase in 100 mM AAB, pH 7.0) 
while the other half incubated in AAB.  Samples were shaken vigorously for 24 hours at 
37 degrees C.  Following 24 hours incubation, the leaflets were washed in distilled water 
3x for 5 min, frozen, and lyophilized.  Enzyme solutions were saved for DMMB 
analyses. 
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3.2.4 GAG Quantification: Hexosamine Assay 
Total hexosamine content can be measured using the hexosamine assay as 
previously reported.  Elson and Morgan’s modified hexosamine assay was used to 
measure GAG-related hexosamines.  Lyophilized GAG digested samples were weighed, 
digested in 2 mL 6 N HCl (24 hours, 96 degrees C), and dried under nitrogen gas.  
Samples were resuspended in 2 mL 1M sodium chloride and reacted with 2 ml of 3% 
acetyl acetone in 1.25 M sodium carbonate.  4 mL ethanol and 2 ml of Ehrlich’s reagent 
(0.18M p-dimethylaminobenzaldehyde in 50% ethanol containing 3N HCl) were added, 
and solutions left for 45 min to allow the color to develop.  A pinkish-red color is 
indicative of tissue hexosamine quantities, and the absorbance was read at 540 nm.  A set 
of D(+)-glucosamine standards were used. 
 
3.2.5 GAG Quantification: DMMB Assay 
Tissue lysates from GAG digestion were analyzed using the DMMB assay for 
sulfated GAGs which are released into the enzyme or buffer solution as in section 3.2.3.  
The following solutions were pipetted into each well of a 96-well plate: 20μL tissue 
digest, 30μL PBE buffer (100 mM Na2HPO4, 5 mM EDTA, pH7.5), and 200μL DMMB 
reagent (40 mM NaCl, 40 mM Glycine, 46μM DMMB, pH 3.0).  These were compared 
to chondroitin sulfate (0-1.25μg) standards, and absorbance measured at 525 nm.  
Absorbance was read immediately to prevent degradation of the GAG-DMMB dye 
complex, using the μQuant spectrophotometer (BIO-TEK instruments, Winooski, VT). 
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3.2.6 Collagen and Elastin Stabilization of Porcine Aortic Cusps 
Aortic valve leaflets were cut in half symmetrically, rinsed in nanofiltered water, 
blotted dry, frozen, lyophilized, and weighed.  Half cusps were incubated in 1.2 ml of 5 
U/ml elastase in 100 mM Tris, 1mM CaCl2, 0.02% NaN3 (pH 7.8) for 24 hours, or 75 
U/mL collagenase (Type VII) in 50 mM Tris, 10 mM CaCl2, 0.02% NaN3 (pH 8.0) for 48 
hours at 37 C while shaking at 650 RPM.  Enzyme liquid was saved for further studies, 
digested cusps rinsed in nanofiltered water, blotted dry, frozen, lyophilized, and weighed.  
Percent weight loss was calculated.  Cusps were saved for histology or hexosamine 
analyses. 
 
3.2.7 GAG Stability during Fixation Process 
 To evaluate which fixation step is most critical to GAG preservation, NCIE 
fixation was performed.  Six cusps were removed following each fixation step (N: 
neomycin, NC: carbodiimide, NCI: isopropanol, and NCIE: ethanol incubation), and 
compared to glutaraldehyde control.  Cusps were exposed to GAG degrading enzymes as 
in Sec 3.2.3 and assayed for GAG content using hexosamine (3.2.4) and DMMB (3.2.5) 
assays.  Additionally, carbodiimide crosslinking followed by isopropanol was used as a 
control for NCIE fixation to evaluate the effect of neomycin on preserving GAGs. 
 
3.2.8 Subdermal Implantation 
Following fixation, all tissues were rinsed thoroughly three times in 30 minute 
washes of sterile saline, and remained in sterile saline until implantation.  Male juvenile 
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Sprague-Dawley rats were anesthetized by inhalation of 3% isoflurane gas. A dorsal 
surgical incision was made, and two subdermal pockets created on either side of the 
sagittal plane. Cusps were blotted dry and positioned to lie as flat as possible in the 
pocket. One cusp was placed per pocket. Incisions were closed with surgical staples and 
tissues retrieved after 10 or 15 weeks. The rats were euthanized with carbon 
dioxide/oxygen mix.  Half cusps were saved for hexosamine (Sec 3.2.4), and mineral 
content (Sec 3.2.10). The middle section was placed in 10% Neutral Buffered Formalin 
(NBF) and saved for histological analysis.  The remaining sections were placed 
immediately on dry ice, and frozen at -80 °C as soon as possible. 
 
3.2.9 Storage Studies 
 To assess the effect of storage in 20% isopropanol solution, whole cusps were 
stored for up to ten months.  Glut and NCIE valves were fixed, treated with 80% ethanol 
in 50 mM HEPES (pH 7.4), then returned to a solution of 20% isopropanol in 50 mM 
HEPES (pH 7.4) or 0.2% glutaraldehyde in 50 mM HEPES (pH 7.4) for NCIE and Glut, 
respectively.  Enzymatic degradation of GAGs was quantified using hexosamine (3.2.4) 
and DMMB (3.2.5) assays following treatment with GAG degrading enzymes (3.2.3).  
Extracellular matrix stability was tested by treating with collagenase and elastase (3.2.6), 
and uniaxial mechanical properties were also tested (3.2.11). 
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3.2.10 Mineral Content: Calcium and Phosphorous Analysis 
Half cusps from subdermal implantation studies were frozen, lyophilized, 
weighed, and acid hydrolyzed in 2 mL 6N Ultrex II HCl for 20 hours at 96ºC.  Samples 
were dried under nitrogen gas, resuspended in 1 mL 6N Ultrex II HCl, and centrifuged at 
high speeds to separate any remaining particles.  Samples were diluted in atomic 
absorption matrix (0.5% Lanthanum oxide in 0.3N Ultrex II HCl) and assayed for 
calcium using the 3030 Atomic Absorption Spectrophotometer (Perkin-Elmer, Norwalk, 
CT).  Samples were diluted to the calibration curve range, and normalized to dry tissue 
weight. 
For phosphorous content and to verify calcium content, samples were further 
analyzed by Clemson University faculty in the Clemson University Agricultural Service 
Laboratory.  Samples were diluted 1:50 in nanofiltered water, elemental analysis 
performed using the Spectro Acros ICP Spectrometer (SPECTRO Analytical Instruments, 
Kleve, Germany) to measure calcium and phosphorous content in ppm.  Dilution ratios 
were used to calculate element content of the sample, and values were normalized to dry 
sample weight. 
 
3.2.11 Histological Assessment 
Radial cross sections were taken from the center of cusps, fixed in 10% neutral 
buffered formalin, embedded in paraffin wax, and sectioned at 5 μm for light microscopy 
analysis.  Dahl’s alizarin red stain with light green counterstain was used to visualize 
calcium deposition in implanted samples; calcium deposits appear red.  Verhoeff van 
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Giesen’s stain (VVG) was used to verify elastin preservation; elastin appears black while 
collagen appears red.  Alcian blue staining with nuclear fast red counterstain was used to 
visualize GAGs; the blue color is indicative of GAG presence. 
 
3.2.12  Statistical Analysis 
Results are expressed as mean ± standard error of the mean (SEM).  All negative 
data is expressed as zero ± SEM.  Statistical analyses were performed using one way 
analysis of variance (1-way ANOVA).  Tukey’s least significant difference was used for 
multiple comparisons.  Differences between the means were determined using least 
significant difference at a 95% significance level (α=0.05). 
 
3.3 Results 
3.3.1 GAG Stability during Fixation Process 
Valve leaflets were tested following each fixation step to determine which step is 
most critical to GAG preservation.  Each cusp was cut in half, and treated with either a 
buffer, or solution containing chondroitinase and hyaluronidase (collectively termed 
GAGase).  Acid hydrolysis and hexosamine analysis followed to determine GAG 
content.  GAG content in the buffer shows the total amount of GAGs in the tissue 
following fixation, while GAG content following enzyme digestion shows the relative 
resistance to GAG degrading enzymes.  An important fact to note is that much more 
variation exists when testing tissue than when testing manufactured materials.  As such, 
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more variation may exist between test groups or samples harvested from separate 
animals.   
   
Figure 3.1. GAGs remaining following digestion per Sec 3.2.3.  Measured using 
hexosamine assay. Demonstrates (A) increased stability following carbodiimide 
crosslinking, and (B) no stability change with addition of isopropanol or ethanol 
treatments.  *Denotes significant difference between groups (p<0.05, n=6). 
 
For simplicity in comparison, GAG groups were separated (Figure 3.1).  
Neomycin treatment alone lost more GAGs than GLUT (GLUT: 121.91±14.81 μg GAG 
/ 10 mg dry tissue, N: 24.80±7.33 μg GAGs / 10 mg dry tissue, p<0.001) when exposed 
to enzymes.  These results show that treatment with neomycin alone does not crosslink 
tissue, but rather needs a chemical crosslinker, or activator, to bind to the tissue.  This 
was shown when carbodiimide treatment was added to the tissue.  GAG enzyme 
resistance increased the most following the carbodiimide crosslinking step (NC: 
152.37±7.33 μg GAGs / 10 mg dry tissue, N: 24.80±7.33 μg GAGs / 10 mg dry tissue, 
p<0.001).  Additionally, no difference in GAGase resistance was measured following 
isopropanol and ethanol treatments.  The final treatments were also compared (GLUT vs. 
A B 
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NCIE).  When final treatments were compared, NCIE with ethanol end treatment 
(187.92±8.21 63 μg GAG / 10 mg dry tissue) had much more favorable enzyme 
resistance, compared with GLUT (121.91±14.81 63 μg GAG / 10 mg dry tissue, 
p=0.003). 
 
Figure 3.2. Sulfated GAGs lost into solution after enzymatic digestion, as measured by 
DMMB assay.  (A) Neomycin alone lost more GAGs than any group. (B) Fewer GAGs 
lost in undigested tissue, while large variances were measured in later treatments 
following digestion. *Statistical difference between treatments (p<0.05, n=6). 
 
The DMMB assay is a colorimetric method to measure the GAG content removed 
as a result of buffer or enzyme treatment, and can be used to confirm hexosamine 
analysis.  The DMMB results confirmed the analysis for fixation step mediated GAG 
levels and GAGase resistance (Figure 3.2).  Generally, DMMB results are the inverse of 
hexosamine, since DMMB measures the amount of GAGs removed with enzyme 
treatment, rather than the amount remaining in the tissue.  Significantly higher levels of 
GAGs were measured in the neomycin treated tissue (102.63±9.53 μg GAGs / 10 mg dry 
tissue, p<0.001) than all other tissue.  This further confirms that neomycin alone does not 
B A 
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stabilize GAGs, but that an initiator is required for neomycin incorporation into 
crosslinking.  GAG levels in the enzyme liquid were reduced when treated with 
carbodiimide crosslinking (N: 102.63±9.53 μg GAGs / 10 mg dry tissue, NC: 21.29±9.54 
μg GAGs / 10 mg dry tissue, p<0.001), which shows crosslinking occurred to stabilize 
GAGs.  GAGase resistance did not improve following isopropanol treatment, but did 
after ethanol incubation (NCI: 34.27±6.00 μg GAGs / 10 mg dry tissue, NCIE: 
11.21±3.93 μg GAGs / 10 mg dry tissue, p=0.009).  Final treatment with ethanol appears 
to have better GAGase resistance than GLUT (27.31±7.56 μg GAGs / 10 mg dry tissue), 
but large variance did not result in a significant difference between GLUT and any other 
treatment group. 
 
3.3.2 Long-term Subdermal Implantation 
 Long term subdermal implantation in juvenile rats creates an accelerated model 
for calcification of implants, and the effect of in vivo enzyme levels on implants.  Using 
this model, cusps were treated using tissue fixation strategies, and implanted for 10 and 
15 weeks.  This model was used to assess calcium and phosphorous levels and GAG 
stabilization following implantation.  Calcium and phosphorous levels are used to 
demonstrate the progression of mineralization in calcification.  Both NCIE and GLUT 
groups were pretreated with 80% ethanol, a proven calcification reduction method 
[133,147,184-186]. 
 Calcium and phosphorous levels were much lower in NCIE than GLUT at both 
time points, and are expressed in μg Ca or P / mg dry tissue weight (Figure 3.3) 
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(p<0.001).  At 10 weeks, NCIE accumulated very little calcium (GLUT: 161.26±16.15, 
NCIE: 4.06±2.39). At 15 weeks, NCIE had accumulated more, but still significantly less 
than GLUT (GLUT: 203.63±8.15, NCIE: 20.91±13.28).  The rate of progression was 
similar for phosphorous levels.  At 10 weeks, NCIE had minimal phosphorous 
accumulation (GLUT: 70.65±6.62, NCIE: 4.51±1.25).  After 15 weeks, NCIE still 
accumulated minimal phosphorous levels (GLUT: 85.21±3.23, NCIE: 11.45±5.73).  
Mineralization results were confirmed through Alizarin Red staining (Figure 3.4). 
 
Figure 3.3.  Mineralization following long term subdermal implantation, demonstrating 
greatly reduced mineral formation levels in NCI groups than GLUT.  * Denotes statistical 
difference between groups (p<0.05, n=10). 
 
 Mineralization progression can be evaluated by calculating calcium to 
phosphorous (Ca:P) ratios.  This ratio increased as implantation time increased, but 
values are indicative of immature hydroxyapatite formation.  At 10 weeks, NCIE and 
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GLUT Ca:P ratios were 0.64±0.12 and 2.26±0.03; at 15 weeks, NCIE and GLUT Ca:P 
ratios were 0.99±0.20 and 2.39±0.02.  However, none of these ratios are consistent with 
natural hydroxyapatite Ca:P ratios (1.67), indicating that there may be another 
mechanism of mineralization progression. 
  
  
Figure 3.4. Histological cross sections of long term subcutaneously implanted porcine 
aortic cusps.  Alizarin red stain for calcium. Dark red is indicative of calcium deposits. 
[A] GLUT 10 weeks, [B] NCI 10 weeks, [C] GLUT 15 weeks, [D] NCI 15 weeks. 
 
Following 10 weeks implantation, resistance to GAG degrading enzymes was 
measured (Figure 3.5).  Samples were exposed to GAG degrading enzymes to determine 
potential to maintain enzyme resistance after 10 weeks implantation.  Enzyme resistance 
was greatly increased in NCIE than GLUT implants (GLUT: 0±2.04 μg GAGs / 10 mg 
dry tissue, NCIE: 73.11±34.11 μg GAGs / 10 mg dry tissue, p<0.001).  Any GAGs 
A 
C 
B 
D 
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remaining in implanted tissue in the GLUT group were removed when GAG degrading 
enzymes were used.  For reference, unimplanted tissue contained higher levels of GAGs 
than implanted tissue, but the NCIE lost fewer GAGs than GLUT tissue (Preimplant 
GLUT: 78.88±2.82 μg GAGs / 10 mg dry tissue, NCIE: 127.82±7.29 μg GAGs / 10 mg 
dry tissue) during implantation.  This demonstrates that GAGs were stabilized against 
enzymes prior to implantation, and also that some in vivo mechanism is involved in 
decreasing GAG stability.  These results were confirmed using the Alcian blue stain for 
GAGs (Figure 3.6). 
 
  
Figure 3.5. GAG stability following implantation, as measured by hexosamine assay. (A) 
Following 10 weeks implantation, samples were digested to determine stability. (B) 
Following 15 weeks implantation, samples were evaluated for total GAG content. 
*Statistical difference between groups (p<0.05, n=10). 
 
Following 15 weeks implantation, GAG levels remaining in implanted cusps were 
measured using the hexosamine assay (Figure 3.5).  These tissues were not treated with 
A B 
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enzymes, but rather absolute GAG content remaining following implantation was 
measured.  GLUT lost all GAGs during implantation, while NCIE retained a significant  
  
   
Figure 3.6. Histological cross sections of long term subcutaneously implanted porcine 
aortic cusps.  Alcian Blue stain, blue is indicative of GAG presence. [A] GLUT 10 
weeks, [B] NCI 10 weeks, [C] GLUT 15 weeks, [D] NCI 15 weeks. 
 
percentage of the GAGs present in unimplanted tissue (GLUT: 0± 3.58 μg GAGs / 10 
mg dry tissue, NCIE: 122.94±8.20 μg GAGs / 10 mg dry tissue, p<0.001).  For 
comparison, unimplanted tissues contained more GAGs in NCIE than in GLUT as well 
(GLUT: 130.80±9.73 μg GAGs / 10 mg dry tissue, NCIE: 169.73±34.11 μg GAGs / 10 
mg dry tissue).  No significant difference was measured between baseline groups, 
allowing good comparison between implanted groups for GAG loss. These results 
C 
B A 
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suggest that significant levels of GAGs are retained in NCI treated tissue even at 15 
weeks of implantation.  These results were confirmed using the Alcian blue stain for 
GAGs (Figure 3.6). 
 
3.3.3 Storage Studies 
 A ten month storage study was performed on the NCIE and GLUT groups to 
assess the efficacy of isopropanol as a storage solution.  GAG levels and GAGase 
resistance, as well as elastase and collagenase resistance were measured.  These tests and 
their results are a step towards evaluating the shelf life for chemically fixed valves. 
 
Figure 3.7.  GAG stability following 10 months storage in GLUT or isopropanol, as 
measured by hexosamine assay. *Statistical difference between groups (p<0.05, n=6). 
 
The hexosamine assay was performed on NCIE and GLUT samples following 
incubation in either GAG degrading enzymes or buffer (Figure 3.7).  Absolute GAG 
levels in the tissue remained higher in NCIE treated tissue than GLUT following storage 
(GLUT: 137.80±9.07 μg GAGs / 10 mg dry tissue, NCIE: 223.13±9.81 μg GAGs / 10 mg 
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dry tissue, p<0.001).  Further, the NCIE group exhibited higher GAGase resistance 
following storage when compared to GLUT (GLUT: 128.46±5.60 μg GAGs / 10 mg dry 
tissue, NCIE: 165.71±9.84 μg GAGs / 10 mg dry tissue, p=0.003).  These data show that 
there are also more GAGs following digestion of the NCIE group than the GLUT group 
exposed to buffer (p=0.049), demonstrating that NCIE enzyme resistance even maintains 
higher levels of GAGs than GLUT tissue not exposed to enzymes, over a ten month 
storage period. 
 
Figure 3.8. GAGs lost into enzyme liquid during digestion, following 10 months storage, 
measured by DMMB assay. *Statistical difference between groups (p<0.05, n=6). 
 
 DMMB assay was performed on GAGase liquid for both NCIE and GLUT groups 
which were stored for ten months, in order to confirm the hexosamine assay results 
(Figure 3.8).  The data showed roughly equal levels of GAGs released when treated with 
a buffer, but also exhibited higher levels of GAGs released from the NCIE group than 
GLUT (GLUT: 48.47±2.04 μg GAGs / 10 mg dry tissue, NCIE: 61.50±5.34 μg GAGs / 
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10 mg dry tissue p=0.033), when exposed to GAG degrading enzymes.  These results 
show that more GAGs were released from NCIE tissue than GLUT when treated with 
GAGase.  This corresponds with hexosamine data.  However, there were also higher 
overall levels of GAGs in NCIE tissue compared with GLUT, when the hexosamine 
assay was performed. 
 
 
Figure 3.9.  Extracellular matrix stability following 10 months storage, tested as in 3.2.6. 
Figure demonstrates excellent collagen stability but poor elastin stability in both groups. 
*Denotes statistical difference between groups (p<0.05, n=6). 
 
 Stabilization of the extracellular matrix following ten months of storage was 
evaluated by measuring the percent weight loss when degraded by elastase or collagenase 
(Figure 3.9).  Half cusps were incubated in each solution.  Stability against elastase did 
not increase significantly when treated with NCIE (GLUT: 19.0±4.3% weight loss, 
 78 
NCIE 15.2±2.9% weight loss).  Similarly, collagen stability did not increase, although 
both tissues exhibited excellent collagen stability (GLUT: -3.2±0.7% weight loss, NCIE: 
-4.1±0.5% weight loss).  Negative values may occur in weight loss due to incomplete 
drying, or other sensitivities to weight measurement.  This data shows that treatment with 
neomycin and carbodiimide crosslinking, followed by storage in isopropanol shows no 
difference from glutaraldehyde crosslinking in stabilizing the extracellular matrix.  
Therefore, the experimental (NCIE) group does not perform worse than GLUT, and 
adequately stabilizes elastin and collagen, in addition to stabilizing GAGs.  
 
3.4 Discussion 
 This study’s main objective was to further evaluate the ability of neomycin and 
carbodiimide crosslinking to preserve GAGs in long-term application and storage of 
bioprosthetic heart valve tissue.  Secondary objectives were to determine which steps in 
fixation modalities are most essential to stabilizing GAGs in the tissue, to measure 
resistance to enzyme digestion following long term storage, and measure calcification in 
a long term in vivo model.  Neomycin and carbodiimide crosslinking were previously 
shown to stabilize GAGs in short term models, and were further hypothesized to stabilize 
GAGs in a long term subdermal model and through storage in an aldehyde-less solution.  
GAG stability was measured through exposure of the tissue to a solution of GAG 
degrading enzymes or buffer, followed by the hexosamine assay to measure GAG 
content.  Use of the buffer allowed determination of total GAG content, and GAG content 
was measured following use of the enzyme in order to determine resistance to GAG 
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degrading enzymes.  A long term (10 and 15 week) subdermal juvenile rat model was 
used for accelerated calcification and exposure to physiological enzyme levels.  Mineral 
and hexosamine levels were measured.  Finally, leaflets were further stored for ten 
months, baseline GAG levels measured, and resistance to elastase, collagenase, and 
GAGase measured to determine stability of the extracellular matrix following storage. 
Glutaraldehyde crosslinked tissue is further stored in a solution of dilute 
glutaraldehyde.  Other solutions have been examined for storage; both for GLUT treated 
tissue and other crosslinking methods, including formalin and ethanol.  Previous use of 
isopropanol in conjunction with neomycin and carbodiimide crosslinking exhibited 
excellent properties when used as a collagen stability control for formaldehyde storage 
solution.  In these experiments, only collagenase and collagen denaturation temperatures 
were evaluated, but were found similar to glutaraldehyde treated tissue.  For this purpose, 
isopropanol was chosen for the final storage solution, and to eliminate aldehyde groups in 
the tissue which can exacerbate mineral formation. 
Other clinically used chemical fixation methods tend to focus either on collagen 
crosslinking or calcification reduction.  Calcification remains one of the prominent modes 
of bioprosthetic valve failure.  The absence of GAGs has also been identified to play a 
key role in both calcification increase and reduction of structural stability, which leads to 
degenerative failure.  Through preserving GAGs in bioprosthetic valve tissue, mechanics 
could be improved, while reducing shear forces between fibrosa and ventricularis layers.  
This could increase the durability of the valve tissue, and consequently the time before 
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degenerative failure occurs in vivo.  GAGs also play a role in reducing calcification, so 
by increasing GAG stability, time to calcific stenosis and failure may be reduced as well. 
Tissue preparation techniques from harvesting to initial fixation have been 
previously demonstrated to play a key role in stabilization of GAGs.  The effect of each 
fixation step on the GAG stability was examined in this study in an attempt to show 
which fixation step(s) are critical to GAG stabilization.  Neomycin alone failed to 
adequately stabilize GAGs.  This happens because the amine functionalities in neomycin 
must be activated.  Glutaraldehyde activates amines to form Schiff bases, while EDC 
activates amines to form amide groups.  This was demonstrated by the addition of EDC 
and NHS into the tissue: both levels of GAGs in the tissue and resistance to enzymatic 
degradation were increased.  A sterile storage liquid is required, since valves are 
manufactured in advance with a two year shelf life.  Isopropanol was added to the 
carbodiimide crosslinking to serve as a storage solution, and showed no significant 
addition to GAG stability.  One day of ethanol incubation further increased GAG 
stability.  This mechanism is unknown, but could be due to conformational changes 
created which further inhibit the enzymatic activity. 
 Similar to polymers, chemically treated tissues exhibit optimal properties 
immediately following treatment, before any degradation can occur.  Tissue is not 
implanted immediately following fixation, and so must have a relevant shelf life.  This is 
a time where the implants can be stored and still maintain desired properties for 
application.  Glutaraldehyde or formaldehyde based solutions are typically used for 
BHVs, but these tissues may contain residual aldehydes, toxic to the body if leached.  If 
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elimination of glutaraldehyde treatment is desired, it cannot be used as a storage solution. 
For this purpose, isopropanol was chosen as an alternative storage solution for 
carbodiimide crosslinked valves.   
Extracellular matrix stability was tested following ten months of storage, and 
compared to tissue treated with and stored in glutaraldehyde.  Properties were desired to 
be equivalent to or better than glutaraldehyde.  Equivalent stability of elastin and collagen 
against enzymatic degradation was observed following storage.  A significant amount of 
weight was still lost due to elastase digestion; an elastin-targeted fixation scheme may 
improve this resistance.  In non-enzyme treated tissue, NCIE leaflets contained fewer 
GAGs than GLUT leaflets.  Similarly, GAG-enzyme digested tissue contained higher 
GAG levels in NCIE leaflets than GLUT leaflets.  Further, the GAG levels following 
enzyme treatment in NCIE leaflets still remained higher than the undigested GLUT 
samples.  This indicates that GAGs are maintained even through ten months of storage by 
using the NCIE treatment. Further, other extracellular matrix components did not exhibit 
a change in enzymatic resistance, indicating stability equivalent to GLUT. 
While enzymatic resistance to elastase is shown to be comparable to GLUT, a 
significant amount of elastin was still degraded.  This effect was also previously observed 
in non-stored in vitro studies [144].  Elastin does play a critical role in native valve 
mechanics; fragmentation of elastin also plays a role in both calcific accumulation and 
structural degradation.  Improved stability of elastin may be beneficial to BHVs, and is 
examined in the following chapter. 
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 Following demonstration of the ability to stabilize GAGS in vitro and maintain 
this capacity following storage, long term in vivo stabilization properties were examined 
using a subdermal model.  Potential to reduce calcification was also examined.  
Compared to in vitro testing, resistance to GAG degrading enzymes was decreased in 
NCIE following 10 weeks implantation, but remained significantly higher than GLUT.  
Further, after 15 weeks implantation, significant levels of GAGs remained in the tissue.  
These combined results suggest that GAGs are stabilized against both leaching and in 
vivo degradation, but a mechanism exists in vivo which destabilizes GAGs when exposed 
to in vitro levels of GAG degrading enzymes.  
 A surprising result was that NCIE treatment combined with ethanol incubation 
drastically reduced calcification up to 15 weeks, compared to GLUT and ethanol control 
treatment.  Ethanol incubation has been previously shown to have a marked reduction on 
calcification of implants, even in glutaraldehyde crosslinked tissue [133,147,184,185].  
This effect was not observed in the present study, but lacks a control for ethanol 
treatment.  This experimental design was intentional, since ethanol treatment has proven 
effective, and is used by St Jude Medical in their Linx treatment.  However, it is an 
oversight which doesn’t allow demonstration of the ethanol treatment’s efficacy in the 
current study.  Calcium to phosphorous ratios can be used in calcification studies to show 
the progression of mineralization.  Normal mineralization results in hydroxyapatite-like 
material, with a Ca:P of 1.67.  This ratio was much lower in NCIE treated tissue, possibly 
due to increased levels of phosphate in the tissue.  Conversely, the ratio was higher than 
for hydroxyapatite in GLUT treated tissue, indicating higher levels of calcium than 
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phosphate.  This trend has been observed in previous studies for GLUT treated tissue as 
well.  The reason for altered mineralization progression is not understood, but one 
possibility is that the crosslinking mechanisms play a role in which element accumulates 
at a higher rate. 
 
3.5 Conclusions 
A tissue crosslinking treatment has been presented in this chapter which has the 
potential to stabilize GAGs in bioprosthetic heart valve tissue.  This was shown at 
different steps through the fixation procedure, as well as following ten months storage in 
solution.  Further, no adverse effect to stability of other extracellular matrix components 
was seen following storage.  This treatment was then used to demonstrate GAG stability 
in an in vivo model, with the additional benefit of reduced calcification of the implant.  
The fixation procedure analysis and storage studies present a step towards determining 
necessary steps for manufacturing valves, and their shelf life.  Additionally, the 
implantation studies show the ability of tissue treated using this method to resist 
enzymatic degradation and accumulation of calcific components.  This has the potential 
to increase the durability of BHVs by reducing structural and calcific degradation.  If 
these trends carry over to functional testing, the results present an improved method for 
chemical treatment of BHVs. 
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CHAPTER FOUR 
PGG AND NEOMYCIN ENHANCED EXTRACELLULAR  
MATRIX STABILIZATION 
4.1 Introduction 
 Preserved tissues have been used for bioprosthetic heart valve application for 
decades.  Treatments are applied to this tissue in an effort to reduce the xenogenic tissue 
antigenicity and suppress immune rejection when implanted in a patient.  These 
treatments also create crosslinks in the extracellular matrix, in an effort to preserve it 
against enzymatic degradation and further increase its durability.  Glutaraldehyde is the 
clinical tissue fixative used for BHVs since the 1970s.  This chemical has the ability to 
crosslink proteins, reduce antigenicity (by devitalizing cells), and sterilize the tissue.  
Many of the modern implants fail in an unacceptable time due to calcification and 
structural failure.  Additions or changes to crosslinking modalities may be able to change 
these failure rates. 
 Pentagalloyl glucose has been shown to be effective in stabilizing pure elastin, 
elastin in aortic wall, and interventionally as treatment for diseased elastin in abdominal 
aortic aneurysms.  Elastin plays a key role in tissue biomechanics, and also in 
calcification mechanisms.  Stabilization of elastin against enzymatic degradation may be 
useful in reducing structural failure and elastin-mediated calcification.  Neomycin has 
been shown to stabilize GAGs, which also play a key role in tissue biomechanics and 
calcification.  The incorporation of both these chemicals into glutaraldehyde crosslinking 
strategies may prove beneficial to stabilizing native proteins in porcine aortic leaflets, and 
 85 
consequently increase the durability of these implants.  The effect of this crosslinking on 
stabilizing proteins against both in vitro and in vivo enzymatic degradation, improving 
mechanical properties, and reducing calcification in vivo are examined in the present 
chapter. 
 
4.2 Methods 
4.2.1 Materials 
Sodium chloride, hydrochloric acid, acetyl acetone, calcium chloride, sodium azide, 
isopropyl alcohol, glycine and dibasic sodium phosphate were purchased from Fisher 
Scientific (Fair Lawn, NJ).  Collagenase (VII) from Clostridium histolyticum, 
chondroitinase ABC from Proteus vulgaris, hyaluronidase from bovine testes, 
ammonium acetate, neomycin trisulfate, 1,9-dimethylmethylene blue, D(+) Glucosamine, 
and chondroitin sulfate C salt were purchased from Sigma-Aldrich Corporation (St Louis, 
MO).  Porcine pancreatic elastase was purchased from Elastin Products Co (Owensville, 
MO).  8% EM grade glutaraldehyde was purchased from Polysciences, Inc. (Warrington, 
PA).  Sodium chloride, sodium carbonate, and ethylene diamine tetraacetic salt were 
purchased from Acros Organics (Morris Plains, NJ).  Ultrex II hydrochloric acid and 2-
(N-morpholino) ethanesulfonic salt were purchased from J.T. Baker (Phillipsburg, NJ).  
P-dimethyl aminobenzaldehyde was purchased from Ricca Chemical Co. (Arlington, 
TX).  Ethanol was supplied from Clemson University (Clemson, SC).  4-(2-
hydroxyethyl)-1-piperazinesulfonic acid (HEPES) was purchased from EMD Chemicals 
(Billerica, MA).  Lanthanum oxide (III) was purchased from Alfa Aesar (Ward Hill, 
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MA). Pentagalloyl glucose was purchased from OmniChem (Belgium).  Porcine aortic 
valves were supplied from Snow Creek Meat Processing (Seneca, SC). 
 
4.2.2 Tissue Preparation and Fixation 
 Fresh porcine aortic valves were harvested on site at a local slaughterhouse, Snow 
Creek Meat Processing (Seneca, SC). Valves were excised immediately upon animal 
death, and were removed by incisions just below the aortic cusps, and above the aortic 
sinuses. The valves were transported on ice back to the laboratory, and were thoroughly 
rinsed in 0.9% saline.  Excess muscle tissue, fat, and aortic wall was removed from the 
valve, leaving approximately 2 cm of aortic wall connected to the leaflet.  Following 
rinsing and trimming, whole valves were fixed; or the three cusps were separated by 
cutting along the aortic wall, and fixed immediately.  All fixation steps used 33 mL 
solution per cusp, and carried out at room temperature within four hours of harvesting.  
For pentagalloyl glucose (PGG) solutions, PGG was dissolved in HEPES buffered saline 
using heat, cooled to room temperature, and glutaraldehyde added to 0.6%. 
 
GLUT:  Tissue was placed in 0.6% glutaraldehyde in 50 mM HEPES buffered saline 
(pH 7.4) for 24 hours, solution decanted, and replaced with 0.02% glutaraldehyde in 50 
mM HEPES buffered saline (pH 7.4) for at least six days. 
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PG:  Tissue was placed in pentagalloyl glucose (PGG) in 0.6% glutaraldehyde in 50 mM 
HEPES buffered saline (pH 7.4) for 24 hours, rinsed, and replaced with 0.2% 
glutaraldehyde in 50 mM HEPES buffered saline (pH 7.4) for another six days. 
 
NPG: Tissue was placed in 1 mM neomycin trisulfate in 50 mM MES buffered saline 
(pH 5.5) for one hour under orbital shaking.  Solution was decanted, and fixed according 
to PG method described above. 
 
4.2.3 Enzymatic Stability of GAGs 
Aortic valve leaflets were carefully excised from the aortic wall, and washed 
thoroughly in 100 mM ammonium acetate buffer (AAB) at pH 7.0 3x for 5 minutes.  
Leaflets were cut symmetrically, and one half incubated in 1.2 mL GAG degrading 
enzyme solution (5 U/mL hyaluronidase, 0.1 U/mL chondroitinase in 100 mM AAB, pH 
7.0).  Samples were shaken vigorously for 24 hours at 37 degrees C.  Following 24 hours 
incubation, the leaflets were washed in distilled water 3x for 5 min, frozen, and 
lyophilized.  Enzyme solutions were saved for DMMB analyses. 
 
4.2.4 Collagen and Elastin Stabilization of Porcine Aortic Cusps 
Aortic valve leaflets were cut in half symmetrically, rinsed in nanofiltered water, 
blotted dry, frozen, lyophilized, and weighed.  Half cusps were incubated in 1.2 ml of 5 
U/ml elastase in 100 mM Tris, 1mM CaCl2, 0.02% NaN3 (pH 7.8) for 24 hours, or 75 
U/mL collagenase (Type VII) in 50 mM Tris, 10 mM CaCl2, 0.02% NaN3 (pH 8.0) for 48 
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hours at 37 C while shaking at 650 RPM.  Enzyme liquid was saved for further studies, 
digested cusps rinsed in nanofiltered water, blotted dry, frozen, lyophilized, and weighed.  
Percent weight loss was calculated.  Cusps were saved for histology or hexosamine 
analyses. 
  
4.2.5 GAG Quantification: Hexosamine Assay 
Total hexosamine content can be measured using the hexosamine assay as 
previously reported.  Elson and Morgan’s modified hexosamine assay was used to 
measure GAG-related hexosamines.  Lyophilized GAG digested samples were weighed, 
digested in 2 mL 6 N HCl (24 hours, 96 degrees C), and dried under nitrogen gas.  
Samples were resuspended in 2 mL 1M sodium chloride and reacted with 2 ml of 3% 
acetyl acetone in 1.25 M sodium carbonate.  4 mL ethanol and 2 ml of Ehrlich’s reagent 
(0.18 M p-dimethylaminobenzaldehyde in 50% ethanol containing 3N HCl) were added, 
and solutions left for 45 min to allow the color to develop.  A pinkish-red color is 
indicative of tissue hexosamine quantities, and the absorbance was read at 540 nm.  A set 
of D(+)-glucosamine standards were used. 
 
4.2.6 GAG Quantification: DMMB Assay 
Tissue lysates from GAG digestion were analyzed using the DMMB assay for 
sulfated GAGs which are released into the enzyme or buffer solution as in section 4.2.3.  
The following solutions were pipetted into each well of a 96-well plate: 20μL tissue 
digest, 30μL PBE buffer (100 mM Na2HPO4, 5 mM EDTA, pH7.5), and 200μL DMMB 
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reagent (40 mM NaCl, 40 mM Glycine, 46μM DMMB, pH 3.0).  These were compared 
to chondroitin sulfate (0-1.25μg) standards, and absorbance measured at 525 nm.  
Absorbance was read immediately to prevent degradation of the GAG-DMMB dye 
complex, using the μQuant spectrophotometer (BIO-TEK instruments, Winooski, VT). 
 
4.2.7 Optimization of PGG Concentration 
NPG and PG fixation was performed using various concentrations of PGG 
ranging from 0.05% to 0.15%, with glutaraldehyde used as a control.  All tissues were 
exposed to elastin and collagen degrading enzymes (Sec 4.2.4) and GAG degrading 
enzymes (Sec 4.2.3).  Weight loss was used to evaluate elastin and collagen stability, 
while hexosamine and DMMB analyses were used to evaluate GAG loss (Sec 4.2.5, 
4.2.6). 
 
4.2.8 Subdermal Implantation 
Following fixation, all tissues were treated with 80% ethanol in HEPES, pH 7.4 
for 24 hours and rinsed thoroughly in sterile saline prior to implantation.  Male juvenile 
Sprague-Dawley rats were anesthetized by inhalation of 3% isoflurane gas. A dorsal 
surgical incision was made, and two subdermal pockets created on either side of the 
sagittal plane. Cusps were blotted dry and positioned to lie as flat as possible in the 
pocket. One cusp was placed per pocket. Incisions were closed with surgical staples and 
tissues retrieved after 21 days. The rats were euthanized with a carbon dioxide and 
oxygen mix.  Half cusps were saved for hexosamine (Sec 4.2.5), elastin stability (Sec 
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4.2.4), and mineral content (Sec 4.2.9). The middle section was placed in 10% Neutral 
Buffered Formalin (NBF) and saved for histological analysis.  The remaining sections 
were placed immediately on dry ice, and frozen at -80 °C as soon as possible. 
 
4.2.9 Mineral Content: Calcium and Phosphorous Analysis 
Half cusps from subdermal implantation were lyophilized, weighed, and acid 
hydrolyzed in 2 ml 6N Ultrex II HCl for 20 hours at 96ºC.  Samples were dried under 
nitrogen gas, resuspended in 1 ml 0.01N Ultrex II HCL, and centrifuged at high speeds to 
separate residual particles.  Samples were diluted 1:50 or 1:100 in nanofiltered water, and 
Clemson University faculty performed elemental analysis at the Clemson University 
Agricultural Service Laboratory.  The Spectro Acros ICP Spectrometer (SPECTRO 
Analytical Instruments, Kleve, Germany) was used to measure calcium and phosphorous 
content in ppm.  Dilution ratios were used to calculate element content of the sample, and 
values were normalized to dry sample weight. 
 
4.2.10 Histological Assessment 
Radial cross sections were taken from the center of cusps, fixed in 10% neutral 
buffered formalin, embedded in paraffin wax, and sectioned at 5 μm for light microscopy 
analysis.  Dahl’s alizarin red stain with light green counterstain was used to visualize 
calcium deposition in implanted samples; calcium deposits appear red.  Verhoeff van 
Giesen’s stain (VVG) was used to verify elastin preservation; elastin appears black while 
collagen appears red.  A ferric chloride stain for polyphenols (10% FeCl3 in methanol 
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counterstained in 1% light green) verified the presence of PGG in cusp tissue; 
polyphenols appear black.  Alcian blue staining with nuclear fast red counterstain was 
used to visualize GAGs; the blue color is indicative of GAG presence.  Representative 
photomicrographs were taken using Zeiss Axioscope 2 Plus (Carl Zeiss MicroImaging, 
Inc., Thornwood, NY). 
 
4.2.11 Uniaxial Tensile Testing 
The MTS Synergie 100 (MTS Systems, Eden Prairie, MN) was used for uniaxial 
tensile testing with a 10N load cell, and Testworks 4 software for analysis.  A 12 mm 
long by 4 mm wide tissue stamp cut circumferential or radial tissue sections from the 
center of whole leaflets, immediately prior to testing.  Water maintained hydration of the 
samples, which were placed in custom grips lined with fine sandpaper to protect the 
tissue from tearing.  Samples were preloaded to very small (less than 0.1N) loads, and 
width, thickness, and grip separation recorded.  An extension rate of 12.5 mm/min was 
used to stretch the tissue, and stress-strain curves analyzed for elastic moduli, ultimate 
tensile stress, and extensibility. 
 
4.2.12 Differential Scanning Calorimetry 
Differential scanning calorimetry (DSC) was used to measure the thermal 
denaturation temperature (Td) of collagen.  Samples (3-8 mg) from each of the NPG and 
Glut groups were carefully cut from generally the same region of the cusp, blotted dry, 
and placed flat in hermetically sealed pans .  Samples were tested using a DSC 2920 (TA 
 92 
Instruments, Newcastle, DE).  A pilot run verified the Td range for Glut compared to 
previous results, and the remainder of samples were equilibrated at 20 ºC, and heated at 
10 ºC/min until 105ºC (Glut) or 125ºC (NPG).  A higher maximum temperature was used 
for NPG to ensure no additional peaks occurred due to alternative crosslinks.  The 
denaturation temperature was recorded as the maximum value of the endotherm peak. 
 
4.2.13 Statistical Analysis 
Results are expressed as mean ± standard error of the mean (SEM).  All negative 
data is expressed as zero ± SEM.  Statistical analyses were performed using one way 
analysis of variance (1-way ANOVA).   Multiple comparisons were made using Tukey’s 
least significant difference value.  Differences between the means were determined using 
least significant difference at a 95% significance level (α=0.05). 
 
4.3 Results 
4.3.1 PGG Concentration Optimization 
The optimal concentration of tannic acid or PGG used to preserve aortic elastin 
has been previously determined [126,180,181,183].  To evaluate the optimal PGG 
concentration for preserving elastin in the less elastin-rich porcine aortic valves, leaflets 
were crosslinked using various concentrations of PGG ranging from 0.05% to 0.15%.  
Samples were tested both with and without neomycin treatment.  These samples were 
then exposed to elastin, collagen, and GAG degrading enzymes, and compared to GLUT 
samples to evaluate enzyme resistance.  Elastin and collagen resistance was determined 
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by percent weight loss; low weight loss is indicative of higher enzyme resistance.  GAG 
enzyme resistance was evaluated by use of hexosamine and DMMB assays.  Two key 
differences exist in these assays: (1) hexosamine is performed on the tissue while DMMB 
is performed on the liquid remaining, and (2) hexosamine measures sulfated and non-
sulfated GAGs, while DMMB can only quantify sulfated GAGs. 
Weight loss due to elastase, a measure of elastin stability, was performed on PG 
and GLUT samples (Figure 4.1).  All groups treated with PGG exhibited increased 
elastase resistance (p<0.001) when compared to glutaraldehyde treated tissue (GLUT: 
20.47±0.54, 0.05% PG: 8.82±1.22, 0.10% PG: 5.51±0.43, 0.15% PG: 7.03±1.05 
percent weight loss, p<0.001).  There was no significant separation in elastin stability 
between PGG groups.  This suggests that PGG does indeed stabilize elastin in porcine 
aortic valve cusps when compared to GLUT (a decrease of up to 14.96 percent weight 
loss), but the concentration range did not exhibit a significant effect on elastin stability.  
Therefore, it is possible that smaller concentrations of PGG are required to stabilize 
elastin.  Since there was no separation between PGG concentrations, other tests may be 
significant in determining the optimal concentration. 
Weight loss due to collagenase was performed on PG and Glut samples to verify 
that the addition of PGG does not interfere with collagen crosslinking and stability 
(Figure 4.1).  PG groups exhibited higher variance than GLUT samples, and slightly 
higher values (GLUT: -0.18±0.30, 0.05% PG: -1.18±0.43, 0.10% PG: 2.04±0.55, 
0.15% PG: 4.83±2.29 percent weight loss).  Although no significant difference was 
measured between any treatment groups, collagen stability appeared to decrease slightly 
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with the addition of PGG.  The apparent decrease in collagen stability and increase in 
variability of samples may be an artifact of the test.  Occasionally when enzyme 
resistance is high, test factors can contribute to false negative weight loss, such as 
incomplete rinsing or lyophilization, or poor weight balance resolution.  These results 
show that the addition of PGG does not negatively affect collagen stability at a statistical 
level, and that the concentration of PGG does not have an effect on collagen stability. 
 
Figure 4.1. Extracellular matrix stabilization in PGG and GLUT treated tissue, evaluated 
by digesting with collagenase or elastase. Results demonstrate increase in elastin stability 
using PGG.  *Statistical difference between groups (p<0.05, n=6). 
 
Hexosamine analysis was performed on PG, Glut, and fresh samples to determine 
if PG crosslinking has an effect on GAG preservation (Figure 4.2).  Tissue treated with 
buffer contained equivalent GAG amounts across all groups, which makes the evaluation 
of GAG levels following exposure to GAG degrading enzymes simpler.  All groups were 
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in the range of 250 μg GAGs / 10 mg dry tissue prior to enzyme digestion.  GLUT and 
0.05% PG performed poorly and offered the least resistance to GAG degradation, but still 
retained a relatively high number of GAGs (GLUT: 119.48±30.91 μg GAGs / 10 mg dry 
tissue, .05% PG: 138.35±37.93 μg GAGs / 10 mg dry tissue).  Tissue treated with higher 
concentrations of PGG retained more GAGs following digestion with enzymes (0.10% 
PG: 262.81±8.37 μg GAGs / 10 mg dry tissue, 0.15% PG: 263.23±5.67 μg GAGs / 10 
mg dry tissue).  These groups retained a remarkable 99% more GAGs when treated with 
enzyme.  No significant enzyme resistance difference was observed between GAG 
digested 0.05% PG, Glut, and fresh samples. 
 
Figure 4.2. GAG stability following PG treatment, measured by hexosamine assay.  
Results demonstrate improved GAG stability with higher concentrations of PGG.  
*Denotes statistical difference between experimental groups (p<0.05, n=6). 
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A pilot study was conducted to evaluate enzyme resistance of PG tissues with 
neomycin trisulfate added (NPG, data not shown).  Resistance to elastase and collagenase 
in particular were very promising, demonstrating -0.27±1.11 and 1.61±0.41 percent 
weight loss, respectively.  Following the results of this pilot study, we decided to pursue 
chemical fixation using neomycin, PGG and GLUT (NPG).  The remainder of this 
chapter will focus on optimizing PGG concentration when used with neomycin, and 
further results using the optimized PGG concentration in NPG crosslinking. 
Histological analysis was performed on NPG and GLUT tissue to visualize 
microscopic structures.  Verhoeff van Giesen’s elastic stain, which stains elastin black, 
was used to show increased levels of unfragmented elastin in NPG tissue (Figure 4.3).  
The Alcian blue stain with nuclear fast red counterstain was used to demonstrate higher 
levels of GAGs in NPG than GLUT tissue.  In this stain, GAGs are colored blue (Figure 
4.4).  A polyphenol specific stain utilizing ferric chloride and light green counterstain 
was used to visualize presence of PGG in NPG treated tissue.  Ferric chloride stains 
polyphenols black or a darker color than surrounding tissue (Figure 4.5) 
  
Figure 4.3. Verhoeff van Giesen’s stain for (A) GLUT, (B) NPG treated tissue.  Elastic 
fibers are stained black. 
A B 
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Figure 4.4. Alcian blue stain for GAGs. (A) GLUT, (B) NPG treatments.  GAGs are 
stained blue. 
  
Figure 4.5. Ferric chloride stain for polyphenols. (A) GLUT, (B) NPG treatment.  PGG 
is stained black, but takes on a dark greenish tint due to image processing. 
 
Elastin stability was evaluated on NPG, GLUT, and fresh tissue through 
measuring weight loss due to enzyme degradation (Figure 4.6).  All NPG groups 
exhibited higher resistance to elastase than GLUT or Fresh tissue (Data is expressed in 
percent weight loss; Fresh: 27.93±1.60, GLUT: 18.77±1.83, 0.05% NPG: 10.14±1.06, 
0.10% NPG: 8.61±2.48, 0.15% NPG: 3.97±2.50).  There was no significant separation 
B 
B 
A 
A 
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between NPG groups, although the use of 0.15% NPG greatly increase elastin stability 
compared to GLUT or Fresh controls.  These results suggest that the presence of PGG 
alone at concentrations at least 0.05% is sufficient to preserve elastin when exposed to 
elastase in vitro, when compared to GLUT (a difference of at least 8.63 percent weight 
loss) or fresh (a difference of at least 17.79 percent weight loss).  Elastin stability was 
verified histologically using Verhoeff van Giesen’s stain (Figure 4.7), and stability of 
PGG when exposed to enzymes was further verified histologically using a Ferric 
Chloride stain (Figure 4.8). 
  
Figure 4.6. Extracellular matrix stability in NPG treated tissue, evaluated using elastase 
and collagenase as in 4.2.4.  Results demonstrate excellent collagen and elastin stability 
in NPG tissues.  *Statistical difference between GLUT and experimental group (p<0.05, 
n=6). 
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Figure 4.7. Verhoeff van Giesen’s stain following digestion with (A,C,E) Collagenase or 
(B,D,F) Elastase. (A-B) Fresh, (C-D) GLUT, (E-F) 0.15% NPG.  Note black stained 
elastic fibers are maintained in NPG treated tissue, but not GLUT or Fresh. 
A 
C 
B 
E 
D 
F 
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Figure 4.8. Ferric chloride polyphenol stain following exposure to (A-C) Collagenase 
and (D-F) Elastase.  (A, D) Fresh, (B, E) GLUT, (C, F) 0.15% NPG.  Note overall darker 
stain in NPG tissue, indicative of PGG presence. 
 
A similar trend was observed when collagen stability was evaluated on NPG, 
GLUT, and fresh tissue (Figure 4.6).  GLUT is known to crosslink collagen, so this test is 
intended to show NPG does not negatively affect the GLUT crosslinking.  All crosslinked 
tissue performed better than fresh tissue (Data expressed in percent weight loss; Fresh: 
76.65±1.12, GLUT: 8.03±1.77, 0.05% NPG: 3.88±0.29, 0.10% NPG: 2.00±0.52, 
0.15% NPG: 0.00±2.15, p<0.001).  All concentrations of NPG resulted in greatly 
increased enzyme resistance when compared to GLUT, observed from the drastic 
reduction in weight loss.  However, only the 0.15% and 0.10% treatments were 
statistically significant (p<0.05).  Again, statistical significance was not measured 
F E D 
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between higher concentrations of NPG (0.15% and 0.10% PGG).  However, the stark 
difference in elastin stability was such that 0.15% PGG was pursued.  Extracellular 
matrix stability was verified histologically using Verhoeff van Giesen’s stain (Figure 
4.7). 
 
Figure 4.9.  GAG stability following NPG treatment, measured by hexosamine assay.  
Results demonstrated improved GAG levels and stability following NPG treatment.  
Large variance and possible impurities contributed to high levels in 0.10% NPG group.  
*Statistical difference between GLUT and experimental group (p(0.05, n=6). 
 
NPG and GLUT samples were treated with either a buffer solution to measure 
total GAGs, or a GAG degrading enzyme solution to measure GAG stability.  
Hexosamine analysis followed, in order to evaluate the effect of changing PGG 
concentration on preserving GAGs.  All NPG groups preserved GAGs better than GLUT 
or fresh tissue, as evidenced by higher levels of GAGs remaining following enzyme 
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digestion (All data in μg GAGs / 10 mg dry tissue; Fresh: 78.94±5.71, GLUT: 
119.48±30.91, 0.05% NPG: 250.06±7.64, 0.10% NPG: 238.81±4.92, 0.15% NPG: 
261.87±7.98, p<0.003).  When exposed to enzymes, all NPG groups had significantly 
reduced variation in GAG levels than GLUT treated tissue.  There was a degree of 
separation between 0.15% and 0.10% NPG groups (p=0.034). The 0.15% NPG group 
also exhibited much higher resistance to GAG degrading enzymes than any other fixation 
group.  A large variance of the 0.10% NPG baseline group contributed to this, but enough 
of a difference was seen that, when combined with other enzyme resistance data from 
elastase and collagenase, the 0.15% NPG group was chosen for further studies.  These 
results were confirmed histologically using Alcian blue staining for GAGs (Figure 4.11). 
 
Figure 4.10.  GAG levels in enzyme liquid following digestion, measured by DMMB 
assay.  Data matches hexosamine data in Fig 4.9, except demonstrates lower levels in 
0.10% NPG group, as expected.  *Denotes statistical difference between GLUT and 
experimental group (p<0.05, n=6). 
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Figure 4.11. Alcian blue staining for GAGs. (A) Fresh, (B) GLUT, (C) 0.15% NPG, (D) 
0.15% NPG GAG enzyme treated.  Higher GAG levels are still seen in NPG enzyme 
treated tissue than GLUT or Fresh. 
 
This data was confirmed by measuring quantities of sulfated GAGs lost to 
enzyme digestion through use of the DMMB assay (Figure 4.10).  Undigested samples 
lost the same amount of GAGs between GLUT and NPG groups, and GAG levels were 
drastically decreased relative to fresh tissue.  Digested samples treated with NPG were 
much lower than GLUT or fresh tissue (Data in μg sulfated GAGs / 10 mg dry tissue; 
Fresh: 58.96±3.58, GLUT: 29.73±3.39, 0.05% NPG: 4.41±1.37, 0.10% NPG: 
2.73±0.79, 0.15% NPG: 0.00±0.78, p<0.05).  This confirms results of the hexosamine 
D C 
B A 
 104 
assay, and shows that NPG treated tissue exposed to enzymes loses minimal levels of 
GAGs to the enzyme liquid. 
 
4.3.2 Evaluation of Material Properties 
Differential scanning calorimetry can measure the thermal denaturation 
temperature (Td) of collagen, which is a measure of crosslinking within the tissue (Table 
4.1).  The thermal denaturation temperature is defined as the temperature at the peak of 
the exotherm.  High concentration (0.15% PGG) NPG and GLUT samples were assessed.  
The thermal denaturation temperature was higher for NPG than GLUT (GLUT: 
88.90±0.43ºC, NPG: 94.89±0.61ºC, p<0.001).  The difference between the measured Td’s 
indicates there is a difference between the degree of crosslinking in the NPG and GLUT 
groups.  This further confirms results from extracellular matrix stability against enzyme 
digestion.  The exact mechanism of crosslinking is difficult to measure, but it may be 
contributed to additional collagen crosslinks formed by introducing PGG, or collagen-
elastin crosslinks formed by PGG-Glutaraldehyde complexes. 
 
Treatment 
Thermal Denaturation Temperature (ºC) ± 
SEM (n=6) 
NPG 94.89 ± 0.61 
GLUT 88.90 ± 0.43 
 
Table 4.1.  Mean collagen thermal denaturation temperature, as measured using 
differential scanning calorimetry.  Statistically significant difference (p<0.05, n=6). 
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Figure 4.12.  Representative DSC traces for NPG and GLUT treated tissue. 
 
 
Figure 4.13.  Mechanical uniaxial tensile testing summary.  (A) Lower elastic modulus 
(elastin response region), (B) Upper elastic modulus (collagen response region), (C) Peak 
stress, (D) Tissue extensibility. (p<0.05, n>6). 
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Mechanical testing is necessary to evaluate potential valve performance.  The 
stiffness and extensibility of tissue directly affects fatigue life and can contribute to 
structural degradation and cuspal tears.  The introduction of PGG into GLUT 
crosslinking necessitates the testing of valves to ensure their mechanical properties are 
not adversely affected.  Uniaxial tensile testing measured the upper and lower elastic 
moduli, ultimate tensile stress, and extensibility were measured in both radial and 
circumferential directions.  Valve mechanics are highly complex, and exhibit multiple 
elastic moduli due to the varied properties of elastin, collagen, and their interactions. 
The elastic modulus (E) was used to evaluate tissue stiffness following uniaxial 
testing (Figure 4.13).  Elastin interactions dominate the lower modulus region, which is 
defined as the modulus in the toe region of the stress-strain curve.  Collagen interactions 
begin to take over, and dominate in the upper modulus region, which is the modulus in 
the ascending region of the stress-strain curve.  NPG was compared to GLUT to ensure 
no negative and unwarranted changes to stiffness occurred in either the radial or 
circumferential direction.  In the lower modulus region, NPG was stiffer than GLUT 
tissue in both radial (p=0.001) and circumferential (p=0.014) directions (GLUT radial: 
167.7±18.8 kPa, NPG radial: 387.2±50.2 kPa, GLUT circumferential: 547.0±35.9 kPa, 
NPG circumferential: 1284.7±179.6 kPa).  The increased stiffness of NPG tissue in the 
lower modulus region is believed to be indicative of increased elastin preservation and 
crosslinking.  In the upper modulus region, NPG tissue was less stiff than GLUT tissue in 
the radial and in the same range as GLUT in the circumferential directions (GLUT 
radial: 1859.4±132.6 kPa, NPG radial: 1191.9±193.2 kPa, GLUT circumferential: 
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4375.4±892.5 kPa, NPG circumferential: 4623.3±850.1 kPa).  It is important to note 
that while the difference in the upper modulus in the radial direction is not different at a 
statistical level, NPG presents a marked change in elasticity over GLUT. 
Peak tensile stresses were measured for each group in both circumferential and 
radial directions.  This value shows the crosslinking strength of the tissue, and its ability 
to resist tensile forces.  NPG exhibited higher peak tensile stresses than GLUT in the 
circumferential direction (p=0.011), but was in the same range as GLUT in the radial 
direction (GLUT circumferential: 1233.6±211.7 kPa, NPG circumferential: 
2213.2±279.6 kPa, GLUT radial: 1023.8±80.8 kPa, NPG radial: 892±110.5 kPa). 
Tissue extensibility shows the strain level where collagen mechanics dominate the 
tissue response.  It is defined as the point where the upper modulus crosses the strain axis.  
NPG and GLUT tissue were roughly equivalent in both directions (GLUT radial: 
19.0±3.1, NPG radial: 18.5±3.6, GLUT circumferential: 14.3±2.4%, NPG 
circumferential: 12.4±2.1%).  This result is expected and desired, due to valve 
mechanics.  The tissue must remain more yielding in order to ensure full coaptation. 
 
4.3.3 Rat Subdermal Implantation: Calcification and ECM Stabilization 
Subdermal implantation in juvenile rats provides an accelerated model for 
calcification of implants and exposes them to a wider array of enzymes occurring at 
natural levels.  This allows evaluation of calcification reduction potential and resistance 
to in vivo enzyme levels.  This model was used for 21 days to evaluate the calcium and 
phosphorous levels, GAG stabilization, and elastin stabilization in NPG implants 
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compared to GLUT implants.  Ferric chloride staining confirmed presence of PGG after 
implantation (Figure 4.14).  Both groups were exposed to 24 hour ethanol treatments 
prior to implantation intended to reduce calcification levels.  No rats experienced severe 
immune reactions to the implanted leaflets.   
   
Figure 4.14.  Histological cross sections from 3 weeks subdermal implants.  Ferric 
chloride stain for polyphenol presence in (A) GLUT and (B) NPG treated tissue.  Note 
the overall darker color in NPG tissue, indicative of PGG presence. 
 
Calcium and phosphorous levels were measured and normalized to tissue weight, 
and are both key elements indicative of calcification progression (Figure 4.15).  Calcium 
levels were much reduced in NPG when compared to GLUT tissue (GLUT: 56.24±10.50 
μg Ca / mg dry tissue, NPG: 3.51±0.50 μg Ca / mg dry tissue, p=0.001). These results 
were confirmed using histology.  The large reduction of calcium content in NPG groups 
indicates that either GLUT alone possesses chemical groups which propentiate 
calcification, or that the increased bonds from neomycin and PGG provide some innate 
ability to reduce calcium levels.  Relative levels were confirmed histologically using 
Dahl’s Alizarin Red stain (Figure 4.16). 
B A 
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Figure 4.15.  Mineral content following 3 weeks subdermal implantation.  Both groups 
were treated with ethanol pretreatment, but GLUT mineral levels remained higher than 
NPG. *Statistical difference between groups (p<0.05, n=6). 
  
Figure 4.16. Histological cross section from 3 weeks subdermal implants.  Alizarin red 
stain turns calcium red.  (A) GLUT, and (B) NPG. 
 
Phosphorous is the other major element involved with calcification.  These levels 
typically have a positive correlation with calcium levels.  This pattern was observed in 
the present study (Figure 4.14); NPG tissue contained less phosphorous than GLUT 
treated tissue (GLUT: 27.10±4.84 μg P / mg dry tissue, NPG: 2.07±0.14 μg P / mg dry 
B A 
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tissue, p=0.001).  This trend was expected, since phosphorous levels are associated with 
calcium levels in mineral formation.  
The molar ratios of calcium to phosphorous were calculated, which are used as an 
indication of mineralization purity within the tissue.  The Ca:P molar ratios were 
calculated at 1.68 and 2.06 for NPG and GLUT, respectively.  Natural hydroxyapatite 
exhibits a molar ratio of 1.67.  These data indicate that mineralization in NPG treated 
tissue proceeds naturally to form a hydroxyapatite-like material, while the minerals 
formed in the GLUT group are more calcium-rich, creating a less pure mineral.  Further, 
calcium contained in the tissue may have been protected from mineralization. 
 
Figure 4.17.  GAG levels following 3 weeks implantation.  NPG lost GAGs during 
implantation, and was not statistically different from implanted GLUT.   NPG did show 
excellent stability prior to implantation.  *Statistical difference between groups (p<0.05, 
n=6). 
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Hexosamine levels were also measured in cusps removed after 21 days (Figure 
4.17).  NPG treated tissue retained more GAGs than GLUT treated tissue, but was not 
different at a statistical level due to high variance (GLUT: 77.92±18.86 μg GAGs / 10 
mg dry tissue, NPG: 111.15±12.45 μg GAGs / 10 mg dry tissue).  In an experimental 
oversight, baseline GAG levels were not measured in the same fixation groups.  Still, it is 
important to note that more GAGs were retained in NPG than GLUT. 
 
Figure 4.18. Extracellular matrix stability following 3 weeks subdermal implantation. 
(A) Elastin and collagen stability. NPG still shows improved stability over GLUT tissue. 
*Denotes statistical difference (p<0.05, n=6). (B) Silver stain electrophoresis gel of 
enzyme liquids using a 4-15% gradient gel. Lanes: [1] Standard, [2] NPG, [3] NPG 
implanted, [4] GLUT, [5] GLUT implanted, [6] Fresh.  Note more extensive 
fragmentation in GLUT than NPG, and darker bands in subdermal groups. 
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Figure 4.19.  Histological sections of 3 week implanted tissue.  Verhoeff van Giesen’s 
elastic stain, which stains elastic fibers black.  (A) GLUT, (B) NPG, (C) GLUT elastase, 
(D) NPG elastase.  Note more black elastin fibers in NPG tissue than GLUT, even 
following 3 weeks implantation and elastase treatments.  This demonstrates elastin 
stability following implantation. 
 
Half cusp explants were also exposed to elastase and collagenase to evaluate 
elastin and collagen stability following exposure to an in vivo environment (Figure 4.18).  
The NPG treated tissue exhibited higher elastin stability than GLUT (GLUT: 35.78±2.99 
percent weight loss, NPG: 25.25±1.75 percent weight loss, p=0.016).  Both of these 
groups lost more weight than when in vitro experiments were performed.  In contrast, 
equivalent collagen stability was observed between NPG and GLUT groups following 
A B 
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implantation (GLUT: 16.03±2.15 percent weight loss, NPG: 18.72±3.71 percent weight 
loss).  These results were confirmed histologically using the Verhoeff van Giesen elastic 
stain (Figure 4.19).  Again, these weight loss percentages are higher than what is seen in 
in vitro experiments.  This suggests there are additional mechanisms in an in vitro 
environment which degrade elastin and collagen.  Further possibilities are that small 
amounts of neomycin or PGG may leach out of tissue, or crosslinks may be broken, 
either of which would lower some of the extracellular matrix stability provided by 
crosslinking.  Zymography followed by silver stain was used to compare GLUT and NPG 
elastase liquids; both implanted and unimplanted liquids were analyzed (Figure 4.18).  
GLUT liquids contained smaller protein fragments than NPG, and increased density in 
implanted bands indicates increased levels of protein fragmentation. 
 
4.4 Discussion 
The main objective in this study was to determine whether previously investigated 
elastin stabilization strategies for vascular elastin could be applied to bioprosthetic heart 
valve leaflets.  Pentagalloyl glucose (PGG) treatment used in conjunction with 
glutaraldehyde crosslinking was hypothesized to stabilize elastin in bioprosthetic heart 
valve tissue.  This stabilization was evaluated by treating tissue with a range of PGG 
concentrations, and measuring resistance to elastase enzyme digestion.  The ability to 
maintain collagen crosslinking and resistance to enzymatic degradation was confirmed as 
well.  The potential for PGG to maintain and stabilize glycosaminoglycans (GAGs) in the 
tissue was evaluated.  Following these combined results, neomycin trisulfate was added 
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to further stabilize GAGs in the tissue.  This treatment was also analyzed using the 
aforementioned methods to determine extracellular matrix stabilization.  The effect of 
PGG crosslinking on materials properties was evaluated, specifically thermal 
denaturation temperature and tensile properties.  Finally, an in vivo model was used to 
assess the potential to reduce calcification and maintain extracellular matrix when 
exposed to enzymatic degradation. 
Clinical fixation methods such as glutaraldehyde crosslinking, amino-oleic acid 
treatment, and ethanol treatment, focus on stabilizing collagen the inhibition of calcific 
mineral formation in vivo.  Efficacy in stabilizing collagen has repeatedly been 
demonstrated using collagenase digestion and differential scanning calorimetry to 
measure the degree of collagen stabilization.  No published claims have been made to 
glutaraldehyde treatment or any other treatment’s ability to crosslink and stabilize elastin 
in heart valve materials.  Likewise, no previous treatments have shown similar elastin 
stabilization in bioprosthetic heart valve materials.   
The primary mechanism of glutaraldehyde crosslinking utilizes amine 
functionalities in collagen.  Elastin contains a much lower concentration of amine-based 
residues, and therefore may not have sufficient reactive groups to be crosslinked to a 
significant degree.  This was previously confirmed in vitro by using tritium-labeled 
glutaraldehyde in attempts to crosslink pure elastin [15]. 
Previous attempts have been made to stabilize pure elastin and elastin in porcine 
aortic wall using glutaraldehyde by Isenburg, et al [126,180].  In these attempts, 
glutaraldehyde crosslinking failed to stabilize elastin against elastase digestion.  
 115 
However, the introduction of tannic acid, and later PGG, demonstrated that the use of 
polyphenols in conjunction with glutaraldehyde crosslinking shows a marked reduction in 
elasteolytic degradation. 
Our lab has developed multiple treatments to optimize GAG stability in porcine 
heart valve leaflets, including the addition of neomycin [28,123,141,143,144,158,159], 
carbodiimide crosslinking to replace glutaraldehyde [28,141-144], and periodate 
oxidation [142,145].  When exposed to elastin degrading enzymes, none of these 
treatments has shown complete reduction in gravimetrically measured elastin 
degradation.  Elastin plays a critical role in heart valve mechanics, providing elasticity to 
the tissue, and contributing to a low level of hysteresis via links with collagen.  Elastin 
also contains functional groups which may contribute to calcification in vivo; 
stabilization of these functional groups may improve resistance to calcium deposition.  
Degradation of elastin is also known to contribute to calcification. 
Elastin degradation and elastin-mediated calcification mechanisms are still not 
fully understood.  Elastin-degrading enzymes likely play a large role in elastin 
degradation.  The presence of matrix metalloproteases (MMPs), which regulate 
extracellular matrix remodeling, has been shown to negatively affect elastin degradation 
[43,44].  While all elastin degrading enzymes cannot be represented in an in vitro study, 
pancreatic elastin is accepted as a model for elasteolytic degradation, similar to the use of 
collagenase to study collagen degradation.  This method is typically used to demonstrate 
elastin stability, but may show different results than the use either of a MMP-based in 
vitro model for elastin degradation, or an in vivo model containing native enzyme levels. 
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A phenol-specific histology stain was used to verify the presence of PGG binding 
to the tissue (Figure 4.5), and was denser in areas of the leaflet which are rich in elastin 
fibers.  Elastase mediated digestion was used to show that the presence of PGG can 
effectively protect leaflet elastin from enzymatic degradation.  This result was verified 
gravimetrically (Figure 4.1) and histologically (Figure 4.3).  Polyphenols such as PGG 
have a high affinity for hydrophobic regions; it is therefore thought that they may bind to 
the hydrophobic elastase cleavage sites in elastin.  This seems to be confirmed due to the 
marked reduction in enzyme degradation of elastin. 
The incorporation of additional molecules and crosslinking modalities can 
negatively affect crosslinking benefits via steric hindrance and competitive binding.  
Following the addition of neomycin to PGG and glutaraldehyde treated leaflets, PGG 
binding, elastase digestion, and collagenase digestion were reassessed.  PGG 
incorporation into the tissue and binding was again verified with a phenol specific 
histology stain, and was shown to be concentrated in elastin rich regions of the leaflet.  
The addition of neomycin did not show a marked difference in elastase or collagenase 
digestion compared to PGG and glutaraldehyde crosslinking, either gravimetrically 
(Figure 4.6), histologically (Figure 4.3, Figure 4.7) or using zymography (Figure 4.18).  
The addition of neomycin did improve elastase and collagenase resistance to enzyme 
digestion when compared to GLUT or fresh tissue, however.  This demonstrates that 
neomycin does not have a negative effect on elastin stabilization when added to PGG and 
glutaraldehyde treatment. 
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GAG loss in bioprosthetic heart valves may occur in two phases.  First, the tissue 
preparation technique has been shown to be critical in maintaining near-physiological 
GAG levels in porcine aortic valve leaflets [125].  Though GAGs may be stabilized to 
remain in the tissue, they may be lost following implantation due to cyclic fatigue or 
enzymatic degradation.  Chondroitin sulfate and hyaluronic acid are the two primary 
GAG types present in heart valves.  Therefore, an in vitro combination of chondroitinase 
and hyaluronidase was used to degrade tissue, and evaluate the resistance to enzyme-
mediated GAG loss.  Following successful results of this treatment, GAG loss was 
evaluated using an in vivo subdermal model in juvenile rats.  The accelerated metabolism 
in this small scale animal model allows for faster evaluation of materials in an in vivo 
environment. 
The addition of neomycin was used to enhance stabilization of GAGs.  This effect 
has previously been shown to be compatible with glutaraldehyde treatment, but never in 
the presence of PGG.  No negative effect on GAG stabilization was demonstrated by 
incorporating neomycin into PGG and glutaraldehyde crosslinking.  In fact, synergistic 
effects may exist between neomycin and PGG, due to additional functional groups 
available for crosslinking.  Neomycin is a known hyaluronidase inhibitor with multiple 
amine functionalities, while pentagalloyl glucose has multiple phenolic hydroxyl groups.  
The presence of multiple functionalities for linkage to proteins presents that a synergistic 
effect may exist.  GAGs were stabilized in tissue and against enzymatic degradation in 
vitro.  This demonstrates that the combination of neomycin and PGG maintains 
neomycin’s ability to stabilize GAGs in porcine aortic leaflets. 
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Collagen crosslinking of tissue was verified by measuring the collagen thermal 
denaturation temperature (Td) of the tissue using differential scanning calorimetry (DSC).  
Collagen stability was further measured gravimetrically via collagenase digestion.  DSC 
involves heating two pans: one empty reference pan, and the other containing small piece 
of hydrated tissue. They are heated at a constant rate, and heat flow is measured in the 
tissue sample.  The thermal denaturation temperature is found by measuring the 
maximum endothermic peak.  This analysis is similar to measuring glass transition 
temperatures in polymers.  The NPG group exhibited an increased collagen thermal 
denaturation temperature over GLUT, indicating that additional crosslinking occurs.  This 
crosslinking could have provided several different linkage types. Elastin naturally 
contains linkages to collagen in heart valves.  As elastin is stabilized, these elastin-
collagen crosslinks exhibit increased stability, explaining the increase in collagen Td.  
GLUT treatment already poses good resistance to collagenase digestion, but the NPG 
group was shown to perform even better at preventing weight loss due to collagenase 
digestion, possibly preventing it altogether.  This may be because PGG or neomycin 
binds to functionalities present in collagen which are not affected by glutaraldehyde 
treatment. 
Crosslinking of tissue alters mechanical properties by providing increased bonds 
and interactions between extracellular matrix components.  The upper elastic modulus is 
dominated by collagen interactions, while the lower elastic modulus is dominated by 
elastin interactions.  For the purpose of this study, the strain at which the transition 
between these response occurs is defined as tissue extensibility.  Excessive stiffness 
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increase has been correlated with decreased durability, while decreased extensibility is 
also detrimental. 
Lower elastic moduli increased with the addition of neomycin and PGG to GLUT 
treated tissue.  This is due to elastin crosslinking since the formation of crosslinks 
between elastic fibers can correspond with increased tissue stiffness.  Upper elastic 
moduli were altered only in the radial direction, in which stiffness decreased in NPG 
tissue.  This decrease in stiffness may be beneficial to valve mechanics, and allow the 
valve to perform better during opening and closing phases.  No significant differences in 
tensile stresses and extensibility were observed.  This shows that addition of neomycin 
and PGG into the treatment does not adversely affect these properties, which is 
significant since GLUT is already used clinically.   
While the uniaxial tensile model can be used to simply show one-dimensional 
biomechanics of valve tissue, the aortic valve is much more complex.  Biaxial testing and 
further examination of molecular mechanics, while not performed in this study, would 
prove beneficial to understanding the crosslinking mechanisms and suitability for aortic 
valve material.  Additionally, comparison to fresh (untreated) tissue would be important 
as another control to determine the effects of NPG crosslinking on valve tissue. 
An in vivo subdermal rat model was used to compare mineralization of NPG 
treated tissue to GLUT treated tissue.  This model allows accelerated calcification 
compared to humans.  Both tissues were treated using ethanol preincubation, which 
reduces calcification by extracting phospholipids and causing collagen conformational 
changes.  NPG exhibited much lower calcium and phosphorous levels than GLUT treated 
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tissue.  Several mechanisms of action may be responsible here.  First, GAGs have been 
thought to inhibit BHV calcification due to a mechanism as yet unknown [20,158].  This 
has been shown by demonstrating calcium levels both when removing GAGs from the 
tissue, and covalently binding GAGs within the tissue.  Second, PGG may bind to 
residues in elastin which normally play a role in BHV calcification.  This result is similar 
to what was previously observed when using tannic acid and GLUT to stabilize aortic 
wall [180]. 
The in vivo model was also used to characterize extracellular matrix stability by 
measuring GAG levels, and stability of elastin and collagen.  Following implantation, 
increased levels of elastase and collagenase digestion were observed in both NPG and 
GLUT treatments, both gravimetrically and histologically.  Three mechanisms may be 
responsible for this: first, PGG is reversibly bound to the tissue.  Second, exposure to 
physiological enzyme levels weakens the tissue and increases susceptibility to enzyme-
induced degradation.  The third possibility is that increased levels of cells and cellular 
debris remain attached upon implantation, even after rinsing in saline following removal 
from the animal.  This would artificially inflate the initial weight; if removed during 
enzyme digestion, the weight loss would increase.  No known studies have been 
performed following subdermal implantation using elastase digestion or collagenase 
digestion, so the increased weight loss relative to in vitro experiments prior to 
implantation may be normal.  Zymography analysis of elastase liquids showed that 
changes in protein fragmentation patterns did not occur following implantation of the 
leaflets in the subdermal model, when compared to elastase liquids of unimplanted tissue 
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(Figure 4.18).  GAG levels remained higher in NPG treated tissue, although the 
difference was not evident at a statistical level.  Baseline GAG levels were not measured 
prior to implantation, so there is no baseline to compare in vivo GAG levels to draw 
further conclusions.  However, the in vivo model did show differences in elastin stability, 
collagen stability, and calcification in NPG compared to GLUT. 
 
4.5 Conclusions 
The addition of PGG to glutaraldehyde crosslinking results in stabilization of 
elastin and further stabilization of collagen to enzymatic degradation.  The addition of 
neomycin to this treatment enhances the effect, and also increases GAG stability.  
Materials properties such as stiffness, tensile strength, and thermal denaturation 
temperature were measured, and demonstrated that NPG crosslinking did alter properties 
relevant to elastin, but not collagen properties from GLUT treatment.  When a subdermal 
model was used to demonstrate the effects of physiological enzyme levels, NPG 
crosslinking maintained these properties, and also reduced calcification levels.   These 
results show that NPG could be an effective tissue treatment for stabilizing all 
extracellular matrix components. 
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CHAPTER FIVE 
CONCLUSIONS AND RECOMMENDATIONS 
While they have been in use for decades, durability of bioprosthetic heart valves 
remains a concern, contributing to early failure rates and limited patient potential.  
Structural deterioration due to both inadequate chemical treatment of tissue and 
calcification accumulation in vivo are the primary modes of failure, resulting in most 
valves failing with 12-15 years of implantation.  The standard glutaraldehyde 
crosslinking treatment stabilizes collagen, but fails to stabilize other extracellular matrix 
components.  This leads to exacerbation of valve deterioration when collagen damage 
occurs.  Glutaraldehyde is also implicated in calcification of bioprosthetic heart valves.  
For these reasons, alternative fixation methods may improve the durability and functional 
lifetime of bioprosthetic heart valve implants.   
Two fixation methods have been presented to further stabilize the extracellular 
matrix.  Neomycin-mediated carbodiimide crosslinking is intended to stabilize 
glycosaminoglycans (GAGs) within the tissue to prevent their loss prior to implantation 
and degradation in vivo.  Substitution of formalin with isopropanol as a storage solution 
aims to maintain properties following storage, and negate the negative effects 
formaldehyde has on durability and calcification.  GAGs stabilization was shown prior to 
implantation and degradation in vitro, as well as following storage and long term 
subdermal implantation.  This treatment also demonstrated the added benefit of reducing 
calcification in a subdermal model.  The substitution of formalin with isopropanol for 
storage appears to preserve these properties in storage.  In addition to stabilizing GAGs, 
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carbodiimide crosslinking induces stabilization of collagen similar to or better than 
glutaraldehyde following storage.  However, carbodiimide crosslinking still fails to 
stabilize elastin, leaving it open to degradation and subsequent calcification. 
Neomycin and pentagalloyl glucose enhanced glutaraldehyde crosslinking aims to 
stabilize elastin and GAGs against enzymatic degradation.  This was shown in vitro and 
in an in vivo subdermal model and also exhibited calcification reduction potential when 
compared with tissue treated with glutaraldehyde and ethanol alone.  Increased levels of 
crosslinking were observed, as evidenced by higher thermal denaturation temperatures 
and slight increase in stiffness response in the elastin region.  No previous techniques 
have attempted elastin crosslinking for heart valve leaflet application, so it is difficult to 
determine whether this increase in elastin stiffness will have negative implications in 
valve biomechanics and durability without further investigation. 
These two treatments pose potential for use in bioprosthetic heart valves, but 
more investigation is required to further understand their viability.  Carbodiimide 
crosslinking is promising, since it eliminates the use of toxic glutaraldehyde.  Evaluation 
of more complex biomechanics, long term storage and cyclic fatigue testing are the next 
steps towards evaluating neomycin and carbodiimide for heart valve application.  In 
depth biomechanical analysis, in particular biaxial, could shed light on whether more 
optimal biomechanics are exhibited.  Longer term storage needs to be performed in order 
to evaluate the shelf life for preserving GAGs.  Finally, cyclic fatigue testing can evaluate 
the functional viability and durability of these heart valve implants.  Following 
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appropriate viability determination, a sheep model can be used to evaluate in vivo 
functionality and hemocompatibility. 
The same studies should be performed for pentagalloyl glucose and neomycin 
enhanced glutaraldehyde crosslinked tissues in order to evaluate their viability.  To begin, 
all chemical treatments should be optimized for concentration and duration of treatment 
in order to maximize performance and mechanical properties.  In particular, more in 
depth analysis of biomechanics, and the effect of stabilizing all extracellular matrix 
components on biomechanics needs to be evaluated.  Following previous models, it 
would be beneficial to examine resistance to buckling, hysteresis, and the performance in 
biaxial testing.  Microstructure evaluation using scanning or tunneling electron 
microscopy may help show what changes actually occur to the tissue.  Further evaluation 
into which order of fixation provides optimal stability and mechanical properties would 
also be beneficial, as well as demonstrating any reversibility in PGG binding.  
Pentagalloyl glucose shows promising ability to reduce elastin degradation; further 
studies should be performed to elucidate any dependence on glutaraldehyde, and if 
possible, investigate its use in alternative fixation modalities. 
To summarize, two methods for stabilizing extracellular matrix components in 
bioprosthetic heart valves have been evaluated, but studies have mostly been limited to 
biochemical analysis including resistance to enzymes and calcification reduction.  More 
in depth analysis of the biomechanical effects of these fixation methods needs to be 
examined, and further investigation into the implications of stabilization on valve 
durability.  
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